<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2022-03-11T01:03:08Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:6347271" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:6347271</identifier>
        <datestamp>2019-02-02</datestamp>
        <setSpec>plosone</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article">
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">PLoS One</journal-id>
              <journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id>
              <journal-id journal-id-type="publisher-id">plos</journal-id>
              <journal-id journal-id-type="pmc">plosone</journal-id>
              <journal-title-group>
                <journal-title>PLoS ONE</journal-title>
              </journal-title-group>
              <issn pub-type="epub">1932-6203</issn>
              <publisher>
                <publisher-name>Public Library of Science</publisher-name>
                <publisher-loc>San Francisco, CA USA</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC6347271</article-id>
              <article-id pub-id-type="pmcid">PMC6347271</article-id>
              <article-id pub-id-type="pmc-uid">6347271</article-id>
              <article-id pub-id-type="pmid">30682037</article-id>
              <article-id pub-id-type="doi">10.1371/journal.pone.0210041</article-id>
              <article-id pub-id-type="publisher-id">PONE-D-18-35035</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Research Article</subject>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Infectious Diseases</subject>
                    <subj-group>
                      <subject>Infectious Disease Control</subject>
                      <subj-group>
                        <subject>Vaccines</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Infectious Diseases</subject>
                    <subj-group>
                      <subject>Viral Diseases</subject>
                      <subj-group>
                        <subject>Viremia</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Infectious Diseases</subject>
                    <subj-group>
                      <subject>Disease Vectors</subject>
                      <subj-group>
                        <subject>Insect Vectors</subject>
                        <subj-group>
                          <subject>Mosquitoes</subject>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and Life Sciences</subject>
                  <subj-group>
                    <subject>Species Interactions</subject>
                    <subj-group>
                      <subject>Disease Vectors</subject>
                      <subj-group>
                        <subject>Insect Vectors</subject>
                        <subj-group>
                          <subject>Mosquitoes</subject>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and Life Sciences</subject>
                  <subj-group>
                    <subject>Organisms</subject>
                    <subj-group>
                      <subject>Eukaryota</subject>
                      <subj-group>
                        <subject>Animals</subject>
                        <subj-group>
                          <subject>Invertebrates</subject>
                          <subj-group>
                            <subject>Arthropoda</subject>
                            <subj-group>
                              <subject>Insects</subject>
                              <subj-group>
                                <subject>Mosquitoes</subject>
                              </subj-group>
                            </subj-group>
                          </subj-group>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and Life Sciences</subject>
                  <subj-group>
                    <subject>Molecular Biology</subject>
                    <subj-group>
                      <subject>Molecular Biology Techniques</subject>
                      <subj-group>
                        <subject>Artificial Gene Amplification and Extension</subject>
                        <subj-group>
                          <subject>Polymerase Chain Reaction</subject>
                          <subj-group>
                            <subject>Reverse Transcriptase-Polymerase Chain Reaction</subject>
                          </subj-group>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Research and Analysis Methods</subject>
                  <subj-group>
                    <subject>Molecular Biology Techniques</subject>
                    <subj-group>
                      <subject>Artificial Gene Amplification and Extension</subject>
                      <subj-group>
                        <subject>Polymerase Chain Reaction</subject>
                        <subj-group>
                          <subject>Reverse Transcriptase-Polymerase Chain Reaction</subject>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Tropical Diseases</subject>
                    <subj-group>
                      <subject>Neglected Tropical Diseases</subject>
                      <subj-group>
                        <subject>Dengue Fever</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Infectious Diseases</subject>
                    <subj-group>
                      <subject>Viral Diseases</subject>
                      <subj-group>
                        <subject>Dengue Fever</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and Life Sciences</subject>
                  <subj-group>
                    <subject>Immunology</subject>
                    <subj-group>
                      <subject>Vaccination and Immunization</subject>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Immunology</subject>
                    <subj-group>
                      <subject>Vaccination and Immunization</subject>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Public and Occupational Health</subject>
                    <subj-group>
                      <subject>Preventive Medicine</subject>
                      <subj-group>
                        <subject>Vaccination and Immunization</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and life sciences</subject>
                  <subj-group>
                    <subject>Organisms</subject>
                    <subj-group>
                      <subject>Viruses</subject>
                      <subj-group>
                        <subject>RNA viruses</subject>
                        <subj-group>
                          <subject>Flaviviruses</subject>
                          <subj-group>
                            <subject>Dengue Virus</subject>
                          </subj-group>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and Life Sciences</subject>
                  <subj-group>
                    <subject>Microbiology</subject>
                    <subj-group>
                      <subject>Medical Microbiology</subject>
                      <subj-group>
                        <subject>Microbial Pathogens</subject>
                        <subj-group>
                          <subject>Viral Pathogens</subject>
                          <subj-group>
                            <subject>Flaviviruses</subject>
                            <subj-group>
                              <subject>Dengue Virus</subject>
                            </subj-group>
                          </subj-group>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Pathology and Laboratory Medicine</subject>
                    <subj-group>
                      <subject>Pathogens</subject>
                      <subj-group>
                        <subject>Microbial Pathogens</subject>
                        <subj-group>
                          <subject>Viral Pathogens</subject>
                          <subj-group>
                            <subject>Flaviviruses</subject>
                            <subj-group>
                              <subject>Dengue Virus</subject>
                            </subj-group>
                          </subj-group>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and Life Sciences</subject>
                  <subj-group>
                    <subject>Organisms</subject>
                    <subj-group>
                      <subject>Viruses</subject>
                      <subj-group>
                        <subject>Viral Pathogens</subject>
                        <subj-group>
                          <subject>Flaviviruses</subject>
                          <subj-group>
                            <subject>Dengue Virus</subject>
                          </subj-group>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and Life Sciences</subject>
                  <subj-group>
                    <subject>Immunology</subject>
                    <subj-group>
                      <subject>Vaccination and Immunization</subject>
                      <subj-group>
                        <subject>Vaccine Development</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Immunology</subject>
                    <subj-group>
                      <subject>Vaccination and Immunization</subject>
                      <subj-group>
                        <subject>Vaccine Development</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Public and Occupational Health</subject>
                    <subj-group>
                      <subject>Preventive Medicine</subject>
                      <subj-group>
                        <subject>Vaccination and Immunization</subject>
                        <subj-group>
                          <subject>Vaccine Development</subject>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Biased efficacy estimates in phase-III dengue vaccine trials due to heterogeneous exposure and differential detectability of primary infections across trial arms</article-title>
                <alt-title alt-title-type="running-head">Biased efficacy estimates in dengue vaccine trials: A simulation study</alt-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-9915-8056</contrib-id>
                  <name>
                    <surname>España</surname>
                    <given-names>Guido</given-names>
                  </name>
                  <role content-type="http://credit.casrai.org/">Conceptualization</role>
                  <role content-type="http://credit.casrai.org/">Formal analysis</role>
                  <role content-type="http://credit.casrai.org/">Investigation</role>
                  <role content-type="http://credit.casrai.org/">Methodology</role>
                  <role content-type="http://credit.casrai.org/">Software</role>
                  <role content-type="http://credit.casrai.org/">Visualization</role>
                  <role content-type="http://credit.casrai.org/">Writing – original draft</role>
                  <xref ref-type="aff" rid="aff001">
                    <sup>1</sup>
                  </xref>
                  <xref ref-type="corresp" rid="cor001">*</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Hogea</surname>
                    <given-names>Cosmina</given-names>
                  </name>
                  <role content-type="http://credit.casrai.org/">Conceptualization</role>
                  <role content-type="http://credit.casrai.org/">Investigation</role>
                  <role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
                  <xref ref-type="aff" rid="aff002">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Guignard</surname>
                    <given-names>Adrienne</given-names>
                  </name>
                  <role content-type="http://credit.casrai.org/">Conceptualization</role>
                  <role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
                  <xref ref-type="aff" rid="aff002">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-5227-1406</contrib-id>
                  <name>
                    <surname>ten Bosch</surname>
                    <given-names>Quirine A.</given-names>
                  </name>
                  <role content-type="http://credit.casrai.org/">Conceptualization</role>
                  <role content-type="http://credit.casrai.org/">Methodology</role>
                  <role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
                  <xref ref-type="aff" rid="aff001">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Morrison</surname>
                    <given-names>Amy C.</given-names>
                  </name>
                  <role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
                  <xref ref-type="aff" rid="aff003">
                    <sup>3</sup>
                  </xref>
                  <xref ref-type="aff" rid="aff004">
                    <sup>4</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0003-4367-3849</contrib-id>
                  <name>
                    <surname>Smith</surname>
                    <given-names>David L.</given-names>
                  </name>
                  <role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
                  <xref ref-type="aff" rid="aff005">
                    <sup>5</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Scott</surname>
                    <given-names>Thomas W.</given-names>
                  </name>
                  <role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
                  <xref ref-type="aff" rid="aff004">
                    <sup>4</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Schmidt</surname>
                    <given-names>Alexander</given-names>
                  </name>
                  <role content-type="http://credit.casrai.org/">Conceptualization</role>
                  <role content-type="http://credit.casrai.org/">Methodology</role>
                  <role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
                  <xref ref-type="aff" rid="aff002">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Perkins</surname>
                    <given-names>T. Alex</given-names>
                  </name>
                  <role content-type="http://credit.casrai.org/">Conceptualization</role>
                  <role content-type="http://credit.casrai.org/">Formal analysis</role>
                  <role content-type="http://credit.casrai.org/">Funding acquisition</role>
                  <role content-type="http://credit.casrai.org/">Investigation</role>
                  <role content-type="http://credit.casrai.org/">Methodology</role>
                  <role content-type="http://credit.casrai.org/">Resources</role>
                  <role content-type="http://credit.casrai.org/">Supervision</role>
                  <role content-type="http://credit.casrai.org/">Visualization</role>
                  <role content-type="http://credit.casrai.org/">Writing – original draft</role>
                  <xref ref-type="aff" rid="aff001">
                    <sup>1</sup>
                  </xref>
                  <xref ref-type="corresp" rid="cor001">*</xref>
                </contrib>
              </contrib-group>
              <aff id="aff001">
                <label>1</label>
                <addr-line>Department of Biological Sciences and Eck Institute for Global Health, University of Notre Dame, Notre Dame, IN, United States of America</addr-line>
              </aff>
              <aff id="aff002">
                <label>2</label>
                <addr-line>GlaxoSmithKline, Rockville, MD, United States of America</addr-line>
              </aff>
              <aff id="aff003">
                <label>3</label>
                <addr-line>United States Naval Medical Research Unit No. 6, Lima, Peru</addr-line>
              </aff>
              <aff id="aff004">
                <label>4</label>
                <addr-line>Department of Entomology and Nematology, University of California, Davis, CA, United States of America</addr-line>
              </aff>
              <aff id="aff005">
                <label>5</label>
                <addr-line>Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, United States of America</addr-line>
              </aff>
              <contrib-group>
                <contrib contrib-type="editor">
                  <name>
                    <surname>Azman</surname>
                    <given-names>Andrew S.</given-names>
                  </name>
                  <role>Editor</role>
                  <xref ref-type="aff" rid="edit1"/>
                </contrib>
              </contrib-group>
              <aff id="edit1">
                <addr-line>Johns Hopkins Bloomberg School of Public Health, UNITED STATES</addr-line>
              </aff>
              <author-notes>
                <fn fn-type="COI-statement" id="coi001">
                  <p><bold>Competing Interests: </bold>We have read the journal's policy and the authors of this manuscript have the following competing interests: AG, AS and CH are paid employees of, and hold shares in, the GlaxoSmithKline group of companies. There are no patents, products in development or marketed products associated with this research to declare. This does not alter our adherence to PLOS ONE policies on sharing data and materials.</p>
                </fn>
                <corresp id="cor001">* E-mail: <email>guido.espana@nd.edu</email> (GE); <email>taperkins@nd.edu</email> (TAP)</corresp>
              </author-notes>
              <pub-date pub-type="epub">
                <day>25</day>
                <month>1</month>
                <year>2019</year>
              </pub-date>
              <pub-date pub-type="collection">
                <year>2019</year>
              </pub-date>
              <volume>14</volume>
              <issue>1</issue>
              <elocation-id>e0210041</elocation-id>
              <history>
                <date date-type="received">
                  <day>10</day>
                  <month>4</month>
                  <year>2018</year>
                </date>
                <date date-type="accepted">
                  <day>14</day>
                  <month>12</month>
                  <year>2018</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>© 2019 España et al</copyright-statement>
                <copyright-year>2019</copyright-year>
                <copyright-holder>España et al</copyright-holder>
                <license xlink:href="http://creativecommons.org/licenses/by/4.0/">
                  <license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
                </license>
              </permissions>
              <self-uri content-type="pdf" xlink:href="pone.0210041.pdf"/>
              <abstract>
                <p>Vaccine efficacy (VE) estimates are crucial for assessing the suitability of dengue vaccine candidates for public health implementation, but efficacy trials are subject to a known bias to estimate VE toward the null if heterogeneous exposure is not accounted for in the analysis of trial data. In light of many well-characterized sources of heterogeneity in dengue virus (DENV) transmission, our goal was to estimate the potential magnitude of this bias in VE estimates for a hypothetical dengue vaccine. To ensure that we realistically modeled heterogeneous exposure, we simulated city-wide DENV transmission and vaccine trial protocols using an agent-based model calibrated with entomological and epidemiological data from long-term field studies in Iquitos, Peru. By simulating a vaccine with a true VE of 0.8 in 1,000 replicate trials each designed to attain 90% power, we found that conventional methods underestimated VE by as much as 21% due to heterogeneous exposure. Accounting for the number of exposures in the vaccine and placebo arms eliminated this bias completely, and the more realistic option of including a frailty term to model exposure as a random effect reduced this bias partially. We also discovered a distinct bias in VE estimates away from the null due to lower detectability of primary DENV infections among seronegative individuals in the vaccinated group. This difference in detectability resulted from our assumption that primary infections in vaccinees who are seronegative at baseline resemble secondary infections, which experience a shorter window of detectable viremia due to a quicker immune response. This resulted in an artefactual finding that VE estimates for the seronegative group were approximately 1% greater than for the seropositive group. Simulation models of vaccine trials that account for these factors can be used to anticipate the extent of bias in field trials and to aid in their interpretation.</p>
              </abstract>
              <funding-group>
                <award-group id="award001">
                  <funding-source>
                    <institution-wrap>
                      <institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100004330</institution-id>
                      <institution>GlaxoSmithKline</institution>
                    </institution-wrap>
                  </funding-source>
                  <principal-award-recipient>
                    <name>
                      <surname>Perkins</surname>
                      <given-names>T. Alex</given-names>
                    </name>
                  </principal-award-recipient>
                </award-group>
                <award-group id="award002">
                  <funding-source>
                    <institution-wrap>
                      <institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100006108</institution-id>
                      <institution>National Center for Advancing Translational Sciences</institution>
                    </institution-wrap>
                  </funding-source>
                  <award-id>TL1TR001107</award-id>
                  <principal-award-recipient>
                    <contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-9915-8056</contrib-id>
                    <name>
                      <surname>España</surname>
                      <given-names>Guido</given-names>
                    </name>
                  </principal-award-recipient>
                </award-group>
                <award-group id="award003">
                  <funding-source>
                    <institution-wrap>
                      <institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100000060</institution-id>
                      <institution>National Institute of Allergy and Infectious Diseases</institution>
                    </institution-wrap>
                  </funding-source>
                  <award-id>1P01AI098670-01A1</award-id>
                  <principal-award-recipient>
                    <contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-9915-8056</contrib-id>
                    <name>
                      <surname>España</surname>
                      <given-names>Guido</given-names>
                    </name>
                  </principal-award-recipient>
                </award-group>
                <funding-statement>GE, QAtB, ACM, TWS, and TAP acknowledge support from a grant from the US National Institutes of Health – National Institute of Allergy and Infectious Diseases (NIH / NIAID (<ext-link ext-link-type="uri" xlink:href="https://www.niaid.nih.gov/">https://www.niaid.nih.gov/</ext-link>)) award number P01AI098670 (to TWS). This publication was made possible with partial support (GE) from Grant Numbers TL1 TR002531 and UL1 TR002529 (A. Shekhar, PI) from the National Institutes of Health, National Center for Advancing Translational Sciences, Clinical and Translational Sciences Award. GlaxoSmithKline Biologicals SA provided support in the form of salaries for authors AG, AS and CH and of funding in the post-doctoral position of GE. GlaxoSmithKline Biologicals SA, through the affiliated authors, had also a role study design by defining the research question, reviewing and inputting on the model proposal and interpretation of the results. GlaxoSmithKline Biologicals SA had no role in the decision to publish or preparation of the manuscript. Authors affiliated to GSK reviewed and approved the manuscript for publication and are therefore compliant with ICMJE criteria for authorship.</funding-statement>
              </funding-group>
              <counts>
                <fig-count count="7"/>
                <table-count count="3"/>
                <page-count count="23"/>
              </counts>
              <custom-meta-group>
                <custom-meta id="data-availability">
                  <meta-name>Data Availability</meta-name>
                  <meta-value>Data are publicly available from GitHub (<ext-link ext-link-type="uri" xlink:href="https://github.com/confunguido/dengueVaccineTrialHeterogeneities.git">https://github.com/confunguido/dengueVaccineTrialHeterogeneities.git</ext-link>)</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
            <notes>
              <title>Data Availability</title>
              <p>Data are publicly available from GitHub (<ext-link ext-link-type="uri" xlink:href="https://github.com/confunguido/dengueVaccineTrialHeterogeneities.git">https://github.com/confunguido/dengueVaccineTrialHeterogeneities.git</ext-link>)</p>
            </notes>
          </front>
          <body>
            <sec sec-type="intro" id="sec001">
              <title>Introduction</title>
              <p>An estimated 390 million people worldwide experience dengue virus (DENV) infections each year, with approximately 96 million of those showing clinically apparent symptoms [<xref rid="pone.0210041.ref001" ref-type="bibr">1</xref>]. Only one dengue vaccine (Dengvaxia, Sanofi Pasteur) has been licensed to date, although safety concerns have limited its rollout [<xref rid="pone.0210041.ref002" ref-type="bibr">2</xref>]. Beyond Dengvaxia, 22 investigational dengue vaccines are at various stages of development, with six of them in clinical trials [<xref rid="pone.0210041.ref003" ref-type="bibr">3</xref>]. Two tetravalent vaccines have advanced to phase-III clinical trials to evaluate vaccine efficacy against symptomatic, virologically-confirmed dengue disease [<xref rid="pone.0210041.ref004" ref-type="bibr">4</xref>,<xref rid="pone.0210041.ref005" ref-type="bibr">5</xref>]. In addition, 14 investigational Zika vaccines are under development, some of which may also advance to late-phase trials [<xref rid="pone.0210041.ref006" ref-type="bibr">6</xref>]. Late-phase vaccine trials for dengue, Zika, and chikungunya—three viruses with a common mosquito vector in <italic>Aedes aegypti</italic>—share a number of common challenges.</p>
              <p>A major challenge for vaccine trials for these diseases derives from the observation that their transmission is characterized by extensive spatial and temporal heterogeneity. For example, epidemiological studies of dengue in both rural [<xref rid="pone.0210041.ref007" ref-type="bibr">7</xref>] and urban [<xref rid="pone.0210041.ref008" ref-type="bibr">8</xref>] settings in Thailand showed that transmission tends to occur focally at spatial scales of 1 km or less and can be much more intense at some times than others. Similar observations are being made for Zika and chikungunya [<xref rid="pone.0210041.ref009" ref-type="bibr">9</xref>,<xref rid="pone.0210041.ref010" ref-type="bibr">10</xref>]. Some of the complications posed to vaccine trials by such strong spatial and temporal heterogeneity include achieving balanced randomization with respect to exposure across trial arms and correctly anticipating exposure rates in advance of a trial.</p>
              <p>Another complication for vaccine trials for these diseases also derives from heterogeneity in transmission, but at much finer scales. Field studies [<xref rid="pone.0210041.ref011" ref-type="bibr">11</xref>,<xref rid="pone.0210041.ref012" ref-type="bibr">12</xref>] have shown that patterns of <italic>Ae</italic>. <italic>aegypti</italic> blood-feeding are extremely heterogeneous; i.e., most of the mosquito bites are concentrated on a few, while other people are rarely bitten [<xref rid="pone.0210041.ref013" ref-type="bibr">13</xref>]. These heterogeneities apply to individuals within a single household and become compounded even further [<xref rid="pone.0210041.ref014" ref-type="bibr">14</xref>] when layered on top of house-to-house variation in <italic>Ae</italic>. <italic>aegypti</italic> densities [<xref rid="pone.0210041.ref015" ref-type="bibr">15</xref>] and complex patterns of human [<xref rid="pone.0210041.ref016" ref-type="bibr">16</xref>,<xref rid="pone.0210041.ref017" ref-type="bibr">17</xref>] and mosquito [<xref rid="pone.0210041.ref018" ref-type="bibr">18</xref>] movement, which affect human-mosquito contact. This fine-scale variation results in heterogeneity in the number of DENV exposures that trial participants experience, which can lead to bias in estimates of vaccine efficacy for susceptibility (VE<sub>S</sub>) [<xref rid="pone.0210041.ref019" ref-type="bibr">19</xref>] for “leaky” vaccines, which confer partial protection to all vaccinees rather than full protection to a subset [<xref rid="pone.0210041.ref020" ref-type="bibr">20</xref>]. This type of bias applies to VE<sub>S</sub> estimates derived using survival methods, such as Cox regression models, unless trial participants experience homogeneity in exposure [<xref rid="pone.0210041.ref021" ref-type="bibr">21</xref>,<xref rid="pone.0210041.ref022" ref-type="bibr">22</xref>]. In the presence of heterogeneities in exposure, frailty models have been proposed to reduce bias in VE<sub>S</sub> estimates [<xref rid="pone.0210041.ref021" ref-type="bibr">21</xref>]. Measuring exposure or collecting data on risk factors can also help in reducing this bias [<xref rid="pone.0210041.ref022" ref-type="bibr">22</xref>].</p>
              <p>Because heterogeneity in exposure is known to induce bias in VE<sub>S</sub> estimates for leaky vaccines and because there is so much heterogeneity in DENV transmission that would be nearly impossible to account for explicitly in a trial, we used a simulation-based approach to assess the extent to which heterogeneous exposure may bias VE<sub>S</sub> estimates for dengue vaccines. Leveraging detailed historical understanding of DENV transmission in Iquitos, Peru, we used this model to explore plausible outcomes for hypothetical vaccine efficacy trials that were simulated as if they took place at a specific point in time during the past in Iquitos. This exercise is an initial case study on which additional analyses can be developed for other specific settings of interest as data from other vaccine trial sites become available and amenable to modeling.</p>
            </sec>
            <sec sec-type="materials|methods" id="sec002">
              <title>Methods</title>
              <sec id="sec003">
                <title>Trial overview</title>
                <p>We designed a hypothetical, individually randomized phase-III trial of a generic dengue vaccine. The aim of the trial was to evaluate the vaccine efficacy for susceptibility (VE<sub>S</sub>) as a measure of the protective effects of vaccination against the first symptomatic, virologically-confirmed case of dengue caused by any DENV serotype during simulated vaccine trials in Iquitos, Peru. A virologically-confirmed dengue case was defined as febrile illness with temperature ≥ 38°C for at least two consecutive days and a positive result from a reverse-transcriptase polymerase chain reaction (RT-PCR) from a blood sample. This endpoint has been used in phase-III dengue vaccine trials and is recommended by the WHO [<xref rid="pone.0210041.ref023" ref-type="bibr">23</xref>]. We chose to simulate the trial in Iquitos because of its long history of epidemiological studies of dengue, which provide a unique opportunity to parameterize and validate detailed models of DENV transmission [<xref rid="pone.0210041.ref016" ref-type="bibr">16</xref>,<xref rid="pone.0210041.ref024" ref-type="bibr">24</xref>–<xref rid="pone.0210041.ref027" ref-type="bibr">27</xref>]. Iquitos is a city of approximately 370,000 inhabitants, located in the Amazon Basin and accessible only by boat or airplane.</p>
                <p>We simulated the active phase of our hypothetical dengue vaccine trials comparable to previous and ongoing trials [<xref rid="pone.0210041.ref005" ref-type="bibr">5</xref>,<xref rid="pone.0210041.ref028" ref-type="bibr">28</xref>–<xref rid="pone.0210041.ref032" ref-type="bibr">32</xref>] (<xref rid="pone.0210041.t001" ref-type="table">Table 1</xref>), such that ours consisted of regular contacts with study participants for at least 13 months after completion of a full course of vaccination (two doses, two months apart). Simulated trial participants were randomly assigned to a placebo or vaccine arm in a 1:1 ratio. We assumed that the placebo conferred no protection against clinical endpoints and that the vaccine conferred some level of protection defined as an input of the model and estimated as VE<sub>S</sub> with the data collected from the trial. In all simulations, we initialized the trial on June 26, 2009. The period thereafter was characterized by a relatively high force of infection of multiple DENV serotypes [<xref rid="pone.0210041.ref027" ref-type="bibr">27</xref>], which would have been ideal for a trial.</p>
                <table-wrap id="pone.0210041.t001" orientation="portrait" position="float">
                  <object-id pub-id-type="doi">10.1371/journal.pone.0210041.t001</object-id>
                  <label>Table 1</label>
                  <caption>
                    <title>Characteristics of four vaccine trial designs for dengue vaccines, in addition to our virtual trial.</title>
                  </caption>
                  <alternatives>
                    <graphic id="pone.0210041.t001g" xlink:href="pone.0210041.t001"/>
                    <table frame="hsides" rules="groups">
                      <colgroup span="1">
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                      </colgroup>
                      <thead>
                        <tr>
                          <th align="left" rowspan="1" colspan="1">Variable</th>
                          <th align="center" rowspan="1" colspan="1">Sanofi CYD14 [<xref rid="pone.0210041.ref028" ref-type="bibr">28</xref>]</th>
                          <th align="center" rowspan="1" colspan="1">Sanofi CYD 15 [<xref rid="pone.0210041.ref030" ref-type="bibr">30</xref>]</th>
                          <th align="center" rowspan="1" colspan="1">Takeda<break/>[<xref rid="pone.0210041.ref005" ref-type="bibr">5</xref>,<xref rid="pone.0210041.ref032" ref-type="bibr">32</xref>]</th>
                          <th align="center" rowspan="1" colspan="1">Butantan<break/>[<xref rid="pone.0210041.ref004" ref-type="bibr">4</xref>,<xref rid="pone.0210041.ref031" ref-type="bibr">31</xref>]</th>
                          <th align="center" rowspan="1" colspan="1">Virtual trial</th>
                        </tr>
                      </thead>
                      <tbody>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Sample size</td>
                          <td align="center" rowspan="1" colspan="1">10,278</td>
                          <td align="center" rowspan="1" colspan="1">20,875</td>
                          <td align="center" rowspan="1" colspan="1">20,100</td>
                          <td align="center" rowspan="1" colspan="1">16,944</td>
                          <td align="center" rowspan="1" colspan="1">2,324<xref ref-type="table-fn" rid="t001fn001">*</xref></td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Number of sites</td>
                          <td align="center" rowspan="1" colspan="1">12</td>
                          <td align="center" rowspan="1" colspan="1">22</td>
                          <td align="center" rowspan="1" colspan="1">Not specified</td>
                          <td align="center" rowspan="1" colspan="1">Not specified</td>
                          <td align="center" rowspan="1" colspan="1">1</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Vaccine:control ratio</td>
                          <td align="center" rowspan="1" colspan="1">2:1</td>
                          <td align="center" rowspan="1" colspan="1">2:1</td>
                          <td align="center" rowspan="1" colspan="1">1:1</td>
                          <td align="center" rowspan="1" colspan="1">2:1</td>
                          <td align="center" rowspan="1" colspan="1">1:1</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Power</td>
                          <td align="center" rowspan="1" colspan="1">0.90</td>
                          <td align="center" rowspan="1" colspan="1">0.90</td>
                          <td align="center" rowspan="1" colspan="1">-</td>
                          <td align="center" rowspan="1" colspan="1">-</td>
                          <td align="center" rowspan="1" colspan="1">0.90</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Control</td>
                          <td align="center" rowspan="1" colspan="1">Placebo</td>
                          <td align="center" rowspan="1" colspan="1">Placebo</td>
                          <td align="center" rowspan="1" colspan="1">Placebo</td>
                          <td align="center" rowspan="1" colspan="1">Placebo</td>
                          <td align="center" rowspan="1" colspan="1">Placebo</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Target efficacy</td>
                          <td align="center" rowspan="1" colspan="1">0.70</td>
                          <td align="center" rowspan="1" colspan="1">-</td>
                          <td align="center" rowspan="1" colspan="1">-</td>
                          <td align="center" rowspan="1" colspan="1">0.80</td>
                          <td align="center" rowspan="1" colspan="1">0.80</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Lower bound of vaccine efficacy</td>
                          <td align="center" rowspan="1" colspan="1">0.25</td>
                          <td align="center" rowspan="1" colspan="1">0.25</td>
                          <td align="center" rowspan="1" colspan="1">-</td>
                          <td align="center" rowspan="1" colspan="1">0.25</td>
                          <td align="center" rowspan="1" colspan="1">0.30</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Age groups</td>
                          <td align="center" rowspan="1" colspan="1">2–5,6–11, 12–14</td>
                          <td align="center" rowspan="1" colspan="1">9–11, 12–16</td>
                          <td align="center" rowspan="1" colspan="1">4–16</td>
                          <td align="center" rowspan="1" colspan="1">2–6, 7–17,18–59</td>
                          <td align="center" rowspan="1" colspan="1">5–17, 18–45</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Primary endpoint</td>
                          <td align="center" rowspan="1" colspan="1">Symptomatic virologically-confirmed dengue disease</td>
                          <td align="center" rowspan="1" colspan="1">Symptomatic virologically-confirmed dengue disease</td>
                          <td align="center" rowspan="1" colspan="1">Symptomatic virologically-confirmed dengue disease</td>
                          <td align="center" rowspan="1" colspan="1">Symptomatic virologically-confirmed dengue disease</td>
                          <td align="center" rowspan="1" colspan="1">Symptomatic virologically-confirmed dengue disease</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Vaccination schedule</td>
                          <td align="center" rowspan="1" colspan="1">Months: 0, 6, 12</td>
                          <td align="center" rowspan="1" colspan="1">Months: 0, 6, 12</td>
                          <td align="center" rowspan="1" colspan="1">Days: 1, 90</td>
                          <td align="center" rowspan="1" colspan="1">Day 1</td>
                          <td align="center" rowspan="1" colspan="1">Days: 1, 60</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Expected cases</td>
                          <td align="center" rowspan="1" colspan="1">57</td>
                          <td align="center" rowspan="1" colspan="1">57</td>
                          <td align="center" rowspan="1" colspan="1">120</td>
                          <td align="center" rowspan="1" colspan="1">24</td>
                          <td align="center" rowspan="1" colspan="1">68</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Minimum timeframe to estimate VE</td>
                          <td align="center" rowspan="1" colspan="1">1 year</td>
                          <td align="center" rowspan="1" colspan="1">1 year</td>
                          <td align="center" rowspan="1" colspan="1">1 year</td>
                          <td align="center" rowspan="1" colspan="1">1 year</td>
                          <td align="center" rowspan="1" colspan="1">1 year</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Statistical analysis</td>
                          <td align="center" rowspan="1" colspan="1">Incidence density</td>
                          <td align="center" rowspan="1" colspan="1">Incidence density</td>
                          <td align="center" rowspan="1" colspan="1">Survival analysis</td>
                          <td align="center" rowspan="1" colspan="1">Incidence density</td>
                          <td align="center" rowspan="1" colspan="1">Survival analysis</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Safety follow-up</td>
                          <td align="center" rowspan="1" colspan="1">5 years</td>
                          <td align="center" rowspan="1" colspan="1">5 years</td>
                          <td align="center" rowspan="1" colspan="1">4.75 years</td>
                          <td align="center" rowspan="1" colspan="1">5 years</td>
                          <td align="center" rowspan="1" colspan="1">-</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Test for baseline DENV serology</td>
                          <td align="center" rowspan="1" colspan="1">Subset</td>
                          <td align="center" rowspan="1" colspan="1">Subset</td>
                          <td align="center" rowspan="1" colspan="1">Yes</td>
                          <td align="center" rowspan="1" colspan="1">-</td>
                          <td align="center" rowspan="1" colspan="1">Yes</td>
                        </tr>
                      </tbody>
                    </table>
                  </alternatives>
                  <table-wrap-foot>
                    <fn id="t001fn001">
                      <p>*Baseline scenario</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
              </sec>
              <sec id="sec004">
                <title>Vaccine model</title>
                <p>We modeled a hypothetical vaccine with a per-exposure protection (PEP) that represents the reduction in risk of disease that the vaccine confers to an individual following a single exposure to DENV. The vaccine reduces the risk of two separate events: successful DENV infection conditional on exposure (RR<sub>inf|exp</sub>) and clinically apparent dengue fever conditional on DENV infection (RR<sub>dis|inf</sub>), such that
<disp-formula id="pone.0210041.e001"><alternatives><graphic xlink:href="pone.0210041.e001.jpg" id="pone.0210041.e001g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M1"><mml:mrow><mml:msubsup><mml:mrow><mml:mtext>PEP=1-RR</mml:mtext></mml:mrow><mml:mrow><mml:mtext>inf|exp</mml:mtext></mml:mrow><mml:mo>ρ</mml:mo></mml:msubsup><mml:msubsup><mml:mrow><mml:mtext>RR</mml:mtext></mml:mrow><mml:mrow><mml:mtext>(dis|inf)</mml:mtext></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:mo>ρ</mml:mo></mml:mrow></mml:msubsup><mml:mtext>,</mml:mtext></mml:mrow></mml:math></alternatives><label>(1)</label></disp-formula>
where RR<sub>inf|exp</sub>, RR<sub>dis|inf</sub>, and ρ are specified as inputs to the model. Our default assumption was that the vaccine protects equally against infection conditional on exposure and against disease conditional on infection (ρ = 0.5). Our default assumptions about RR<sub>inf|exp</sub> and RR<sub>dis|inf</sub> were that they both equaled 0.447, consistent with an exploratory PEP value of 0.8 as assumed in planning for the ongoing Butantan trial [<xref rid="pone.0210041.ref031" ref-type="bibr">31</xref>]. In our model, the vaccine does not modify the probability of progressing from symptomatic to severe disease, because the focus of our analysis is on the primary endpoint of virologically-confirmed disease rather than the more severe outcomes that can sometimes be associated with dengue. Even though dengue vaccines seem to have heterogeneous effects in protection [<xref rid="pone.0210041.ref029" ref-type="bibr">29</xref>], we assumed constant protection with respect to time since inoculation, serotype, and serostatus, to simplify the vaccine model and to isolate the effect of heterogeneous exposure from the effect of heterogeneous vaccine protection.</p>
              </sec>
              <sec id="sec005">
                <title>Virtual trial procedures</title>
                <p>Our virtual phase-III trial featured three main processes: recruitment, vaccination, and surveillance. These processes comprise eight specific procedures, which are depicted in <xref ref-type="fig" rid="pone.0210041.g001">Fig 1</xref>. The recruitment phase included (1) enrollment of participants and (2) serological testing to assess for previous DENV infection. Vaccination included (3,4) administration of two doses of vaccine two months apart. Next, study personnel (5) captured cases during weekly phone calls to participants, and a proportion of (6) individuals with symptoms notified trial personnel. Confirmation of DENV infection (7) was attempted with a serotype-specific RT-PCR test, and (8) confirmed cases were recorded in surveillance reports. The trial considers only the first case of symptomatic dengue for each individual in estimates of VE<sub>S</sub>.</p>
                <fig id="pone.0210041.g001" orientation="portrait" position="float">
                  <object-id pub-id-type="doi">10.1371/journal.pone.0210041.g001</object-id>
                  <label>Fig 1</label>
                  <caption>
                    <title>Modeling framework and trial procedures.</title>
                    <p>DENV is transmitted by individual mosquitoes that are found indoors. Humans move daily to different types of locations within the city. Infectious mosquitoes transmit DENV through bites to individuals susceptible to the infecting serotype who are present at a location at the same time as mosquitoes seeking a blood meal. The trial consists of eight procedures listed in the figure. The top curve shows the timing of these procedures in reference to DENV transmission dynamics, and the bottom cartoon depicts each of the procedures.</p>
                  </caption>
                  <graphic xlink:href="pone.0210041.g001"/>
                </fig>
                <sec id="sec006">
                  <title>Recruitment</title>
                  <p>We enrolled simulated trial participants during the first two months of the trial. We randomly selected a subset of the simulated population who were 5–45 years old (y.o.). The number of participants was consistent with the desired sample size to achieve a statistical power of 0.9[<xref rid="pone.0210041.ref033" ref-type="bibr">33</xref>], as described in <xref ref-type="supplementary-material" rid="pone.0210041.s001">S1 Text</xref>. Because DENV exposure differs between children and adults, we recruited participants in such a way that half were children (5–17 y.o.) and half were adults (18–45 y.o.). Within each of those two groups, each participant was randomly assigned to the vaccine or placebo arm on a 1:1 basis. Next, a participant’s pre-existing seropositivity to DENV was recorded, which we assumed could be measured accurately for all trial participants. Individuals without previous exposure to DENV were classified as seronegative and individuals with previous exposure to any of the four DENV serotypes were classified as seropositive, without specification of the number or type of the previous DENV infections.</p>
                </sec>
                <sec id="sec007">
                  <title>Vaccination</title>
                  <p>In the simulation, participants received the first dose of the vaccine or placebo on the day of enrollment. The vaccine conferred PEP defined by the vaccine model, whereas the placebo conferred no protection against infection or disease. Each participant received two doses of vaccine or placebo within sixty days of enrollment. This choice was intermediate between two dengue vaccines currently in phase-III trials (Takeda: two doses 90 days apart [<xref rid="pone.0210041.ref032" ref-type="bibr">32</xref>]; Butantan: one dose [<xref rid="pone.0210041.ref031" ref-type="bibr">31</xref>]). We assumed that the full PEP was conferred by the first dose, its longevity boosted by the second dose, and that all trial participants received both doses on schedule. Consistent with observations of modest efficacy despite high immunogenicity in the only dengue vaccine for which efficacy has been assessed [<xref rid="pone.0210041.ref034" ref-type="bibr">34</xref>] and with assumptions of a model developed by a dengue vaccine manufacturer [<xref rid="pone.0210041.ref035" ref-type="bibr">35</xref>], we assumed that the vaccine was leaky: i.e., partial protection applies uniformly to all vaccinees, as opposed to full protection of a subset of vaccinees.</p>
                </sec>
                <sec id="sec008">
                  <title>Surveillance</title>
                  <p>Surveillance started on the day on which the first dose of vaccine was administered, but cases used for the VE<sub>S</sub> analysis were restricted to those that occurred 28 days or more after administration of the second dose, similar to the protocol for the CYD-TDV trials [<xref rid="pone.0210041.ref036" ref-type="bibr">36</xref>]. The surveillance system captured symptomatic cases in two different ways: weekly phone calls to trial participants by trial personnel and self-reporting. Weekly active surveillance contacted participants to inquire about disease symptoms experienced since the last contact with the surveillance system. Half of the individuals with symptoms of dengue fever reported their symptoms during the weekly surveillance phone calls or sought care, which allowed for laboratory diagnosis. Everyone with severe dengue reported their symptoms to the surveillance system. The probability of self-reporting mild dengue cases was higher than estimates of this probability under circumstances outside the context of a trial [<xref rid="pone.0210041.ref037" ref-type="bibr">37</xref>] (5–15%), given that we expect that people would be more likely to use free healthcare provided as part of their participation in the trial. Some DENV infections go undetected because they are asymptomatic or are not virologically-confirmed by the surveillance system. Because these infections are not detected by the surveillance system, their enrollment status in the trial remains unchanged. To confirm the presence of DENV, we simulated an RT-PCR test in participants with two consecutive days of symptoms and up to five days after symptom onset in agreement with current guidelines [<xref rid="pone.0210041.ref038" ref-type="bibr">38</xref>].</p>
                  <p>To simulate virological confirmation of cases, we modeled the sensitivity of a RT-PCR test as a function of time since symptom onset. To obtain such a function, we first obtained 3,000 simulated viremia trajectories from a model of viremia dynamics for primary and post-primary DENV infections that was fitted to data from individuals enrolled in a clinical study in Vietnam [<xref rid="pone.0210041.ref039" ref-type="bibr">39</xref>]. We then applied a fixed limit of detection (LOD) of 10 cDNA copies per ml to the simulated viremia trajectories and recorded the proportion of those 3,000 simulated trajectories that exceeded that LOD at a given time since symptom onset, which we regarded as the sensitivity of RT-PCR at a given time since symptom onset. We then fitted the function
<disp-formula id="pone.0210041.e002"><alternatives><graphic xlink:href="pone.0210041.e002.jpg" id="pone.0210041.e002g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M2"><mml:mrow><mml:msup><mml:mi>S</mml:mi><mml:mi>i</mml:mi></mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mo> </mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mo>−</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msubsup><mml:mi>β</mml:mi><mml:mn>1</mml:mn><mml:mi>i</mml:mi></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>β</mml:mi><mml:mn>2</mml:mn><mml:mi>i</mml:mi></mml:msubsup><mml:mo> </mml:mo><mml:mi>t</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:msup></mml:mrow></mml:mfrac></mml:mrow></mml:math></alternatives><label>(2)</label></disp-formula>
to the simulated values of sensitivity <italic>t</italic> days after symptom onset in primary and post-primary infections <italic>i</italic> using the optim function in R [<xref rid="pone.0210041.ref040" ref-type="bibr">40</xref>], obtaining curves depicted in <xref ref-type="supplementary-material" rid="pone.0210041.s003">S1 Fig</xref>. We assumed that viremia trajectories corresponding to post-primary infections also applied to vaccinated individuals, given that both should exhibit an antibody response to DENV infection that would result in a shortening of DENV infection and, thus, a shorter window of detectability by RT-PCR.</p>
                </sec>
              </sec>
              <sec id="sec009">
                <title>Statistical analyses</title>
                <p>We used surveillance records resulting from a given virtual vaccine trial to estimate VE<sub>S</sub> based on the timing of when trial participants attained the primary endpoint as detected by the surveillance system. The model simulated censored observations; i.e., some individuals dropped out of the trial before being infected, whereas others finished the trial without being exposed to DENV. Ignoring this feature of the data can result in overestimation of vaccine efficacy [<xref rid="pone.0210041.ref019" ref-type="bibr">19</xref>]. We estimated the vaccine efficacy for susceptibility (VE<sub>S</sub>) as a measure of how protective the vaccine was against disease [<xref rid="pone.0210041.ref019" ref-type="bibr">19</xref>]. VE<sub>S</sub> was calculated based on three approaches: incidence rates, survival methods, and transmission probability. Based on incidence rates, VE<sub>S</sub>,<sub>IR</sub> was calculated as
<disp-formula id="pone.0210041.e003"><alternatives><graphic xlink:href="pone.0210041.e003.jpg" id="pone.0210041.e003g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M3"><mml:mrow><mml:msub><mml:mrow><mml:mtext>VE</mml:mtext></mml:mrow><mml:mrow><mml:mtext>S</mml:mtext><mml:mo>,</mml:mo><mml:mtext>IR</mml:mtext></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>c</mml:mi><mml:mi>v</mml:mi></mml:msub><mml:mo>/</mml:mo><mml:msub><mml:mi>y</mml:mi><mml:mi>v</mml:mi></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mi>c</mml:mi><mml:mi>p</mml:mi></mml:msub><mml:mo>/</mml:mo><mml:msub><mml:mi>y</mml:mi><mml:mi>p</mml:mi></mml:msub></mml:mrow></mml:mfrac><mml:mo>,</mml:mo></mml:mrow></mml:math></alternatives><label>(3)</label></disp-formula>
where <italic>c</italic> represents the number of cases detected in each arm of the study, <italic>y</italic> the number of person-years within the trial, and the subscripts <italic>v</italic> and <italic>p</italic> represent the vaccine and placebo arms, respectively [<xref rid="pone.0210041.ref019" ref-type="bibr">19</xref>]. To calculate VE<sub>S</sub> based on survival methods, we estimated VE<sub>S,Cox</sub> with a Cox model in R [<xref rid="pone.0210041.ref040" ref-type="bibr">40</xref>] using the coxph function with default settings [<xref rid="pone.0210041.ref041" ref-type="bibr">41</xref>]. The survival model was implemented with the data represented by the time to first event (or follow-up time) and a binary variable for PCR positivity. In an attempt to account for heterogeneous exposure within the trial, we also considered the addition of a frailty expression—in which heterogeneity in exposure was defined as a random effect by a gamma distribution—to the Cox-regression model and estimated VE<sub>S,frailty</sub> using the same coxph function in R with an additional frailty term specified as frailty(ID, distribution = "gamma").</p>
                <p>The above methods do not require information about the level of exposure of individuals in the trial. Such measures are often used in phase-III trials to measure VE<sub>S</sub> because information on exposure to infection may be unfeasible to obtain in field trials. This task is particularly difficult for mosquito-borne diseases, because individual mosquito bites would need to be recorded to estimate the level of exposure of trial participants. Our model allowed us to record the exact number of exposures that every individual experienced during the trial, defined as an infectious bite received by a susceptible human. Knowledge on the exact number of exposures allowed us to estimate VE<sub>S</sub> based on the probability of transmission ‘p’, which should be robust to heterogeneous exposure. The measure VE<sub>S,p</sub> was defined as
<disp-formula id="pone.0210041.e004"><alternatives><graphic xlink:href="pone.0210041.e004.jpg" id="pone.0210041.e004g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M4"><mml:mrow><mml:msub><mml:mrow><mml:mtext>VE</mml:mtext></mml:mrow><mml:mrow><mml:mtext>S</mml:mtext><mml:mo>,</mml:mo><mml:mtext>p</mml:mtext></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>c</mml:mi><mml:mi>v</mml:mi></mml:msub><mml:mo>/</mml:mo><mml:msub><mml:mi>n</mml:mi><mml:mi>v</mml:mi></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mi>c</mml:mi><mml:mi>p</mml:mi></mml:msub><mml:mo>/</mml:mo><mml:msub><mml:mi>n</mml:mi><mml:mi>p</mml:mi></mml:msub></mml:mrow></mml:mfrac><mml:mo>,</mml:mo></mml:mrow></mml:math></alternatives><label>(4)</label></disp-formula>
where <italic>c</italic><sub><italic>v</italic></sub> and <italic>c</italic><sub><italic>p</italic></sub> represent the number of cases in the vaccine and placebo arm, respectively, and <italic>n</italic><sub><italic>v</italic></sub> and <italic>n</italic><sub><italic>p</italic></sub> represent the total number of exposures in the vaccine and placebo arms, respectively [<xref rid="pone.0210041.ref019" ref-type="bibr">19</xref>]. Comparison between this and other VE<sub>S</sub> measures was used to aid in the interpretation of our results.</p>
              </sec>
              <sec id="sec010">
                <title>Model overview</title>
                <p>We simulated vaccine trials using an agent-based model of DENV transmission that simulates the transmission dynamics of DENV in a population of 200,000 in a core population area of Iquitos, Peru [<xref rid="pone.0210041.ref042" ref-type="bibr">42</xref>,<xref rid="pone.0210041.ref043" ref-type="bibr">43</xref>]. Our model includes simulated daily human movement patterns calibrated to data from retrospective, semi-structured interviews of residents in Iquitos [<xref rid="pone.0210041.ref044" ref-type="bibr">44</xref>,<xref rid="pone.0210041.ref045" ref-type="bibr">45</xref>]. This model has been demonstrated to reproduce the dynamics of all four DENV serotypes [<xref rid="pone.0210041.ref042" ref-type="bibr">42</xref>] and was used to investigate the epidemiological impacts of hypothetical vaccination campaigns to project the population-level impact of Dengvaxia [<xref rid="pone.0210041.ref046" ref-type="bibr">46</xref>,<xref rid="pone.0210041.ref047" ref-type="bibr">47</xref>]. Because a formal description of the version of the transmission model that was used here has been published elsewhere [<xref rid="pone.0210041.ref042" ref-type="bibr">42</xref>], we provide an overview of its key features and assumptions in <xref ref-type="supplementary-material" rid="pone.0210041.s002">S2 Text</xref>.</p>
              </sec>
              <sec id="sec011">
                <title>Model calibration</title>
                <p>We used parameter estimates from the literature wherever possible (<xref rid="pone.0210041.t002" ref-type="table">Table 2</xref>) and calibrated the values of unknown parameters so as to allow the model to generate patterns of transmission within the study area consistent with time-varying incidence of infection estimates from a longitudinal cohort study [<xref rid="pone.0210041.ref027" ref-type="bibr">27</xref>]. Three sets of parameters were calibrated through this process: (1) serotype-specific population immunity on 1 January 2000, when estimates of time-varying, serotype-specific incidence of infection began; (2) time-varying, serotype-specific patterns of unexplained infections from visitors to the study area or residents that were infected outside the study area; and (3) constants for scaling mosquito population density at two different time points during which mosquitoes were collected using different methods. We calibrated these parameters using a particle filtering algorithm described in detail elsewhere (<xref rid="pone.0210041.t003" ref-type="table">Table 3</xref>) [<xref rid="pone.0210041.ref042" ref-type="bibr">42</xref>].</p>
                <table-wrap id="pone.0210041.t002" orientation="portrait" position="float">
                  <object-id pub-id-type="doi">10.1371/journal.pone.0210041.t002</object-id>
                  <label>Table 2</label>
                  <caption>
                    <title>Fixed parameters of the model.</title>
                  </caption>
                  <alternatives>
                    <graphic id="pone.0210041.t002g" xlink:href="pone.0210041.t002"/>
                    <table frame="hsides" rules="groups">
                      <colgroup span="1">
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                      </colgroup>
                      <thead>
                        <tr>
                          <th align="left" rowspan="1" colspan="1">Parameter</th>
                          <th align="center" rowspan="1" colspan="1">Value</th>
                          <th align="center" rowspan="1" colspan="1">Reference</th>
                        </tr>
                      </thead>
                      <tbody>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Mosquito daily movement probability to a nearby house</td>
                          <td align="center" rowspan="1" colspan="1">30%</td>
                          <td align="center" rowspan="1" colspan="1">[<xref rid="pone.0210041.ref048" ref-type="bibr">48</xref>]</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Mosquito daily emergence rates</td>
                          <td align="center" rowspan="1" colspan="1">Consistent with time-varying estimates of adult mosquito death rates and spatiotemporal estimates of Ae. Aegypti density in Iquitos.</td>
                          <td align="center" rowspan="1" colspan="1">[<xref rid="pone.0210041.ref049" ref-type="bibr">49</xref>,<xref rid="pone.0210041.ref050" ref-type="bibr">50</xref>]</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Average interval between blood feeding events (exponential distribution)</td>
                          <td align="center" rowspan="1" colspan="1">Temperature-dependent</td>
                          <td align="center" rowspan="1" colspan="1">[<xref rid="pone.0210041.ref051" ref-type="bibr">51</xref>–<xref rid="pone.0210041.ref053" ref-type="bibr">53</xref>]</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Probability of pathogen transmission to susceptible human conditional on an infectious mosquito bite</td>
                          <td align="center" rowspan="1" colspan="1">1.0</td>
                          <td align="center" rowspan="1" colspan="1">[<xref rid="pone.0210041.ref054" ref-type="bibr">54</xref>]</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Incubation period in the mosquito (lognormal distribution)</td>
                          <td align="center" rowspan="1" colspan="1">
                            <inline-formula id="pone.0210041.e005">
                              <alternatives>
                                <graphic id="pone.0210041.e005g" xlink:href="pone.0210041.e005"/>
                                <mml:math id="M5">
                                  <mml:mrow>
                                    <mml:mi>μ</mml:mi>
                                    <mml:mo>=</mml:mo>
                                    <mml:mi>f</mml:mi>
                                    <mml:mrow>
                                      <mml:mo>(</mml:mo>
                                      <mml:mi>T</mml:mi>
                                      <mml:mo>)</mml:mo>
                                    </mml:mrow>
                                    <mml:mo> </mml:mo>
                                    <mml:mo>,</mml:mo>
                                    <mml:mo> </mml:mo>
                                    <mml:mi>σ</mml:mi>
                                    <mml:mo>=</mml:mo>
                                    <mml:mn>0.451754</mml:mn>
                                  </mml:mrow>
                                </mml:math>
                              </alternatives>
                            </inline-formula>
                          </td>
                          <td align="center" rowspan="1" colspan="1">[<xref rid="pone.0210041.ref055" ref-type="bibr">55</xref>]</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Infectiousness—human symptomatic primary infection</td>
                          <td align="center" rowspan="1" colspan="1">
                            <inline-formula id="pone.0210041.e006">
                              <alternatives>
                                <graphic id="pone.0210041.e006g" xlink:href="pone.0210041.e006"/>
                                <mml:math id="M6">
                                  <mml:mrow>
                                    <mml:msup>
                                      <mml:mi>e</mml:mi>
                                      <mml:mrow>
                                        <mml:mrow>
                                          <mml:mo>(</mml:mo>
                                          <mml:mrow>
                                            <mml:mo>−</mml:mo>
                                            <mml:mn>0.204</mml:mn>
                                            <mml:msup>
                                              <mml:mrow>
                                                <mml:mrow>
                                                  <mml:mo>(</mml:mo>
                                                  <mml:mrow>
                                                    <mml:mi>t</mml:mi>
                                                    <mml:mo>−</mml:mo>
                                                    <mml:msub>
                                                      <mml:mi>t</mml:mi>
                                                      <mml:mi>i</mml:mi>
                                                    </mml:msub>
                                                    <mml:mo>−</mml:mo>
                                                    <mml:mn>5.538</mml:mn>
                                                  </mml:mrow>
                                                  <mml:mo>)</mml:mo>
                                                </mml:mrow>
                                              </mml:mrow>
                                              <mml:mn>2</mml:mn>
                                            </mml:msup>
                                            <mml:mo>/</mml:mo>
                                            <mml:mn>0.999</mml:mn>
                                          </mml:mrow>
                                          <mml:mo>)</mml:mo>
                                        </mml:mrow>
                                      </mml:mrow>
                                    </mml:msup>
                                  </mml:mrow>
                                </mml:math>
                              </alternatives>
                            </inline-formula>
                          </td>
                          <td align="center" rowspan="1" colspan="1">[<xref rid="pone.0210041.ref056" ref-type="bibr">56</xref>]</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Infectiousness—human symptomatic secondary infection</td>
                          <td align="center" rowspan="1" colspan="1">
                            <inline-formula id="pone.0210041.e007">
                              <alternatives>
                                <graphic id="pone.0210041.e007g" xlink:href="pone.0210041.e007"/>
                                <mml:math id="M7">
                                  <mml:mrow>
                                    <mml:msup>
                                      <mml:mi>e</mml:mi>
                                      <mml:mrow>
                                        <mml:mrow>
                                          <mml:mo>(</mml:mo>
                                          <mml:mrow>
                                            <mml:mo>−</mml:mo>
                                            <mml:mn>0.383</mml:mn>
                                            <mml:msup>
                                              <mml:mrow>
                                                <mml:mrow>
                                                  <mml:mo>(</mml:mo>
                                                  <mml:mrow>
                                                    <mml:mi>t</mml:mi>
                                                    <mml:mo>−</mml:mo>
                                                    <mml:msub>
                                                      <mml:mi>t</mml:mi>
                                                      <mml:mi>i</mml:mi>
                                                    </mml:msub>
                                                    <mml:mo>−</mml:mo>
                                                    <mml:mn>5.874</mml:mn>
                                                  </mml:mrow>
                                                  <mml:mo>)</mml:mo>
                                                </mml:mrow>
                                              </mml:mrow>
                                              <mml:mn>2</mml:mn>
                                            </mml:msup>
                                            <mml:mo>/</mml:mo>
                                            <mml:mn>0.999</mml:mn>
                                          </mml:mrow>
                                          <mml:mo>)</mml:mo>
                                        </mml:mrow>
                                      </mml:mrow>
                                    </mml:msup>
                                  </mml:mrow>
                                </mml:math>
                              </alternatives>
                            </inline-formula>
                          </td>
                          <td align="center" rowspan="1" colspan="1">[<xref rid="pone.0210041.ref056" ref-type="bibr">56</xref>]</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Infectiousness—human asymptomatic primary infection</td>
                          <td align="center" rowspan="1" colspan="1">
                            <inline-formula id="pone.0210041.e008">
                              <alternatives>
                                <graphic id="pone.0210041.e008g" xlink:href="pone.0210041.e008"/>
                                <mml:math id="M8">
                                  <mml:mrow>
                                    <mml:msup>
                                      <mml:mi>e</mml:mi>
                                      <mml:mrow>
                                        <mml:mrow>
                                          <mml:mo>(</mml:mo>
                                          <mml:mrow>
                                            <mml:mo>−</mml:mo>
                                            <mml:mn>0.25</mml:mn>
                                            <mml:msup>
                                              <mml:mrow>
                                                <mml:mrow>
                                                  <mml:mo>(</mml:mo>
                                                  <mml:mrow>
                                                    <mml:mi>t</mml:mi>
                                                    <mml:mo>−</mml:mo>
                                                    <mml:msub>
                                                      <mml:mi>t</mml:mi>
                                                      <mml:mi>i</mml:mi>
                                                    </mml:msub>
                                                    <mml:mo>−</mml:mo>
                                                    <mml:mn>5.585</mml:mn>
                                                  </mml:mrow>
                                                  <mml:mo>)</mml:mo>
                                                </mml:mrow>
                                              </mml:mrow>
                                              <mml:mn>2</mml:mn>
                                            </mml:msup>
                                            <mml:mo>/</mml:mo>
                                            <mml:mn>0.999</mml:mn>
                                          </mml:mrow>
                                          <mml:mo>)</mml:mo>
                                        </mml:mrow>
                                      </mml:mrow>
                                    </mml:msup>
                                  </mml:mrow>
                                </mml:math>
                              </alternatives>
                            </inline-formula>
                          </td>
                          <td align="center" rowspan="1" colspan="1">[<xref rid="pone.0210041.ref056" ref-type="bibr">56</xref>]</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Infectiousness—human asymptomatic secondary infection</td>
                          <td align="center" rowspan="1" colspan="1">
                            <inline-formula id="pone.0210041.e009">
                              <alternatives>
                                <graphic id="pone.0210041.e009g" xlink:href="pone.0210041.e009"/>
                                <mml:math id="M9">
                                  <mml:mrow>
                                    <mml:msup>
                                      <mml:mi>e</mml:mi>
                                      <mml:mrow>
                                        <mml:mrow>
                                          <mml:mo>(</mml:mo>
                                          <mml:mrow>
                                            <mml:mo>−</mml:mo>
                                            <mml:mn>0.584</mml:mn>
                                            <mml:msup>
                                              <mml:mrow>
                                                <mml:mrow>
                                                  <mml:mo>(</mml:mo>
                                                  <mml:mrow>
                                                    <mml:mi>t</mml:mi>
                                                    <mml:mo>−</mml:mo>
                                                    <mml:msub>
                                                      <mml:mi>t</mml:mi>
                                                      <mml:mi>i</mml:mi>
                                                    </mml:msub>
                                                    <mml:mo>−</mml:mo>
                                                    <mml:mn>4.883</mml:mn>
                                                  </mml:mrow>
                                                  <mml:mo>)</mml:mo>
                                                </mml:mrow>
                                              </mml:mrow>
                                              <mml:mn>2</mml:mn>
                                            </mml:msup>
                                            <mml:mo>/</mml:mo>
                                            <mml:mn>0.999</mml:mn>
                                          </mml:mrow>
                                          <mml:mo>)</mml:mo>
                                        </mml:mrow>
                                      </mml:mrow>
                                    </mml:msup>
                                  </mml:mrow>
                                </mml:math>
                              </alternatives>
                            </inline-formula>
                          </td>
                          <td align="center" rowspan="1" colspan="1">[<xref rid="pone.0210041.ref056" ref-type="bibr">56</xref>]</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Incubation period in humans</td>
                          <td align="center" rowspan="1" colspan="1">Captured by time-varying infectiousness curve</td>
                          <td align="center" rowspan="1" colspan="1">[<xref rid="pone.0210041.ref055" ref-type="bibr">55</xref>,<xref rid="pone.0210041.ref056" ref-type="bibr">56</xref>]</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Human temporary immunity period (Exponential distribution).</td>
                          <td align="center" rowspan="1" colspan="1">
                            <inline-formula id="pone.0210041.e010">
                              <alternatives>
                                <graphic id="pone.0210041.e010g" xlink:href="pone.0210041.e010"/>
                                <mml:math id="M10">
                                  <mml:mrow>
                                    <mml:mi>λ</mml:mi>
                                    <mml:mo>=</mml:mo>
                                    <mml:mfrac>
                                      <mml:mn>1</mml:mn>
                                      <mml:mrow>
                                        <mml:mn>686</mml:mn>
                                      </mml:mrow>
                                    </mml:mfrac>
                                    <mml:mo> </mml:mo>
                                    <mml:mi>d</mml:mi>
                                    <mml:mi>a</mml:mi>
                                    <mml:mi>y</mml:mi>
                                    <mml:msup>
                                      <mml:mi>s</mml:mi>
                                      <mml:mrow>
                                        <mml:mo>−</mml:mo>
                                        <mml:mn>1</mml:mn>
                                      </mml:mrow>
                                    </mml:msup>
                                  </mml:mrow>
                                </mml:math>
                              </alternatives>
                            </inline-formula>
                          </td>
                          <td align="center" rowspan="1" colspan="1">[<xref rid="pone.0210041.ref042" ref-type="bibr">42</xref>,<xref rid="pone.0210041.ref057" ref-type="bibr">57</xref>]</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Probability of developing symptoms given primary infection</td>
                          <td align="center" rowspan="1" colspan="1">30%</td>
                          <td align="center" rowspan="1" colspan="1">[<xref rid="pone.0210041.ref056" ref-type="bibr">56</xref>]</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Probability of developing symptoms for secondary infection</td>
                          <td align="center" rowspan="1" colspan="1">60%</td>
                          <td align="center" rowspan="1" colspan="1">[<xref rid="pone.0210041.ref056" ref-type="bibr">56</xref>]</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Probability of developing symptoms for tertiary and quaternary infections</td>
                          <td align="center" rowspan="1" colspan="1">10%</td>
                          <td align="center" rowspan="1" colspan="1">[<xref rid="pone.0210041.ref056" ref-type="bibr">56</xref>]</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Probability of severe disease for primary infection, given the apparition of symptoms</td>
                          <td align="center" rowspan="1" colspan="1">11%</td>
                          <td align="center" rowspan="1" colspan="1">[<xref rid="pone.0210041.ref056" ref-type="bibr">56</xref>]</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Probability of severe disease for secondary infection, given the apparition of symptoms</td>
                          <td align="center" rowspan="1" colspan="1">20%</td>
                          <td align="center" rowspan="1" colspan="1">[<xref rid="pone.0210041.ref056" ref-type="bibr">56</xref>]</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Probability of severe disease for tertiary and quaternary infections, given the apparition of symptoms</td>
                          <td align="center" rowspan="1" colspan="1">5%</td>
                          <td align="center" rowspan="1" colspan="1">[<xref rid="pone.0210041.ref056" ref-type="bibr">56</xref>]</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Human demographic rates</td>
                          <td align="center" rowspan="1" colspan="1">Consistent with U.N. estimates</td>
                          <td align="center" rowspan="1" colspan="1">[<xref rid="pone.0210041.ref058" ref-type="bibr">58</xref>]</td>
                        </tr>
                      </tbody>
                    </table>
                  </alternatives>
                </table-wrap>
                <table-wrap id="pone.0210041.t003" orientation="portrait" position="float">
                  <object-id pub-id-type="doi">10.1371/journal.pone.0210041.t003</object-id>
                  <label>Table 3</label>
                  <caption>
                    <title>Calibrated parameters.</title>
                  </caption>
                  <alternatives>
                    <graphic id="pone.0210041.t003g" xlink:href="pone.0210041.t003"/>
                    <table frame="hsides" rules="groups">
                      <colgroup span="1">
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                      </colgroup>
                      <thead>
                        <tr>
                          <th align="left" rowspan="1" colspan="1">Parameter</th>
                          <th align="center" rowspan="1" colspan="1">Reference</th>
                        </tr>
                      </thead>
                      <tbody>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Serotype-specific population immunity on 1 Jan. 2000</td>
                          <td align="left" rowspan="1" colspan="1">Fitted to represent estimates of force of infection [<xref rid="pone.0210041.ref027" ref-type="bibr">27</xref>]</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Time-varying, serotype-specific patterns of imported infections</td>
                          <td align="left" rowspan="1" colspan="1">Fitted to represent estimates of force of infection [<xref rid="pone.0210041.ref027" ref-type="bibr">27</xref>]</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Scaling of mosquito population density</td>
                          <td align="left" rowspan="1" colspan="1">Fitted to represent estimates of force of infection [<xref rid="pone.0210041.ref027" ref-type="bibr">27</xref>]</td>
                        </tr>
                      </tbody>
                    </table>
                  </alternatives>
                </table-wrap>
              </sec>
              <sec id="sec012">
                <title>Simulation experiments</title>
                <p>Our primary goal was to quantify bias in VE<sub>S</sub> estimates insofar as they relate to estimates of individual protection afforded by the vaccine, as defined in our simulation model by PEP. This individual-level interpretation is significant, because VE<sub>S</sub> estimates from standard methods represent a weighted average of vaccine effects at the population level. Therefore, whenever the assumption of homogeneous exposure is not met, VE<sub>S</sub> estimates are specific to exposure patterns in the population where the vaccine was evaluated [<xref rid="pone.0210041.ref022" ref-type="bibr">22</xref>]. To the extent that VE<sub>S</sub> estimates made in this way might be used to inform projections of vaccination impact in other populations (due to what is usually a lack of a direct estimate of PEP), understanding the extent of bias in estimates of PEP based on VE<sub>S</sub> is important [<xref rid="pone.0210041.ref022" ref-type="bibr">22</xref>]. To address this driving question, we performed three simulation experiments under different assumptions about heterogeneity in DENV transmission patterns.</p>
                <sec id="sec013">
                  <title>1. Baseline scenario</title>
                  <p>The trial design under the baseline scenario was described in the Trial Overview and Sample Size sections. In this scenario, the attractiveness of humans to mosquitoes was proportional to the human’s body size [<xref rid="pone.0210041.ref011" ref-type="bibr">11</xref>]. The timeframe of the trial ranged one to three years depending on when 68 virologically-confirmed symptomatic dengue cases were captured. We simulated 1,000 replicates of this trial with an input PEP = 0.8 and quantified the bias of the estimated VE<sub>S</sub> relative to the input PEP. We also simulated the trial with an alternative assumption about the viremia of infected vaccinees, in which their viremia followed that of someone experiencing a natural DENV infection. We quantified differences between estimated VE<sub>S</sub> and simulated PEP under both assumptions of viremia of infected vaccinees.</p>
                  <p>We computed the probability that the point estimate of VE<sub>S</sub> was lower than a specified minimum product profile (MPP) below which the vaccine would not be licensed or further developed. We varied the value of MPP (0.1–0.7) and calculated this probability given a PEP equal to the target product profile (TPP) (VE ≥ 0.8). We varied the value of PEP (0.1–0.95) and computed the proportion of trials resulting in VE<sub>S</sub> falling below MPP = 0.3.</p>
                </sec>
                <sec id="sec014">
                  <title>2. Effects of heterogeneous exposure due to heterogeneous biting</title>
                  <p>Heterogeneity in the number of DENV exposures experienced by participants in each trial arm can affect trial results. In our model, an exposure is defined as a bite from an infected mosquito that would result in a human infection in the absence of vaccination. Hence, placebo participants can only experience one exposure before developing infection. Conversely, participants in the vaccine arm can experience multiple exposures before infection due to the assumption that the vaccine is leaky. We simulated four scenarios about the nature of heterogeneous exposure, illustrated in <xref ref-type="fig" rid="pone.0210041.g002">Fig 2</xref>, to investigate how different forms of exposure heterogeneity affect VE<sub>S</sub> estimates.</p>
                  <fig id="pone.0210041.g002" orientation="portrait" position="float">
                    <object-id pub-id-type="doi">10.1371/journal.pone.0210041.g002</object-id>
                    <label>Fig 2</label>
                    <caption>
                      <title>Four distinct assumptions about heterogeneous DENV exposure.</title>
                      <p>Scenario A represents homogeneous transmission of DENV ignoring mosquitoes and human movement patterns, leading to everyone experiencing the same hazard of exposure to any serotype of DENV. In scenarios B, C, and D, DENV is transmitted by mosquitoes, and human and mosquito movement patterns are considered. Scenario B represents homogeneous attractiveness of different humans to mosquitoes at a given location. Scenario C represents human attractiveness to mosquitoes proportional to human body size. Scenario D represents heterogeneous human attractiveness to mosquitoes based on a gamma distribution with shape 1.43 and scale 1, regardless of their body size.</p>
                    </caption>
                    <graphic xlink:href="pone.0210041.g002"/>
                  </fig>
                  <p>The different forms of exposure heterogeneity that we considered (<xref ref-type="fig" rid="pone.0210041.g002">Fig 2</xref>) come about through:</p>
                  <list list-type="alpha-upper">
                    <list-item>
                      <p>Homogeneous hazard of exposure, in which mosquitoes are bypassed altogether and individuals are infected directly based on a time-varying rate of DENV infection.</p>
                    </list-item>
                    <list-item>
                      <p>Constant attractiveness, in which mosquitoes are equally attracted to all humans for blood feeding at a location.</p>
                    </list-item>
                    <list-item>
                      <p>Attractiveness proportional to body surface area, in which mosquitoes are more likely to bite humans with larger bodies [<xref rid="pone.0210041.ref011" ref-type="bibr">11</xref>].</p>
                    </list-item>
                    <list-item>
                      <p>Heterogeneous attractiveness, in which each individual’s attractiveness is drawn from a gamma distribution with shape <inline-formula id="pone.0210041.e011"><alternatives><graphic xlink:href="pone.0210041.e011.jpg" id="pone.0210041.e011g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M11"><mml:mi>α</mml:mi><mml:mi> </mml:mi><mml:mo>=</mml:mo><mml:mi> </mml:mi><mml:mn>1.43</mml:mn></mml:math></alternatives></inline-formula> and rate <inline-formula id="pone.0210041.e012"><alternatives><graphic xlink:href="pone.0210041.e012.jpg" id="pone.0210041.e012g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M12"><mml:mi>β</mml:mi><mml:mi> </mml:mi><mml:mo>=</mml:mo><mml:mi> </mml:mi><mml:mn>1</mml:mn></mml:math></alternatives></inline-formula>, as informed by data from de Benedictis et al. [<xref rid="pone.0210041.ref012" ref-type="bibr">12</xref>].</p>
                    </list-item>
                  </list>
                  <p>In addition to heterogeneity in attractiveness to mosquitoes, heterogeneous exposure in the transmission model results from spatial heterogeneity in contact between mosquitoes and humans, due to spatial patterns of mosquito abundance and human mobility. This is true for all scenarios except A. In scenario A, infections during a trial occur only by a time-varying hazard of DENV infection. We adjusted this hazard to be the same as the force of infection in the remaining three scenarios so that within the trial the AR would be comparable among scenarios. We compared the distributions of VE<sub>S</sub> estimates under these four scenarios by performing 1,000 simulations, with analogous simulations in each set that had the same sequence of random number seeds to minimize differences due to chance across the four scenarios.</p>
                </sec>
                <sec id="sec015">
                  <title>3. Effect of increased heterogeneity of exposure due to high transmission intensity</title>
                  <p>We hypothesized that phase-III trials in sites with high transmission intensity yield more biased vaccine efficacy estimates than trials performed with moderate to low transmission intensity, due to an increased number of exposures in the vaccine arm. Our goal was to quantify the potential magnitude of this effect in our simulated trials by computing bias in VE<sub>S</sub> estimates in a scenario with high transmission intensity. We achieved variation in transmission intensity by varying mosquito emergence rates, which scale the overall density of adult mosquitoes and have a linear effect on the force of infection. Specifically, we doubled mosquito emergence rates in the high-transmission scenario, and we calculated required sample sizes separately for each trial to attain the same statistical power for VE<sub>S</sub> estimates under both scenarios. With these specifications, we simulated 1,000 replicates for each scenario with paired random seeds to allow the behavior of the simulations to be as comparable as possible.</p>
                </sec>
              </sec>
            </sec>
            <sec sec-type="results" id="sec016">
              <title>Results</title>
              <sec id="sec017">
                <title>1. Baseline scenario</title>
                <p>Analysis of the baseline simulations showed a general pattern of VE<sub>S</sub> underestimating the simulated value of PEP (0.8) when using VE<sub>S,IR</sub> (0.71) and VE<sub>S,Cox</sub> (0.71). Compared to VE<sub>S,IR</sub> and VE<sub>S,Cox</sub>, the frailty model slightly reduced bias in its estimate of VE<sub>S,frailty</sub> (0.73). Knowledge of the number of exposures in each trial arm was associated with a slight overestimation of efficacy by VE<sub>S,p</sub> (0.81) (<xref ref-type="fig" rid="pone.0210041.g003">Fig 3A</xref>). Although these patterns held qualitatively across the full range of assumptions about the extent to which the vaccine protects against infection versus disease (modulated by the parameter ρ), the magnitude of bias in VE<sub>S,IR</sub>, VE<sub>S,Cox</sub>, and VE<sub>S,frailty</sub> was somewhat sensitive to ρ (<xref ref-type="supplementary-material" rid="pone.0210041.s005">S3 Fig</xref>). Specifically, these biases were stronger when protection derived more from reducing the risk of infection conditional on exposure and less from reducing the risk of disease conditional on infection (i.e., ρ closer to 1). The slight upward bias of VE<sub>S,p</sub> by 0.01 was unexpected, because VE<sub>S,p</sub> should be capable of fully accounting for bias due to heterogeneous exposure [<xref rid="pone.0210041.ref019" ref-type="bibr">19</xref>]. We also noted that the extent of bias was different between seropositive (<xref ref-type="fig" rid="pone.0210041.g003">Fig 3B</xref>) and seronegative (<xref ref-type="fig" rid="pone.0210041.g003">Fig 3C</xref>) groups. In particular, bias towards the null was 0.02 higher in the seropositive group for all VE<sub>S</sub> measures (<xref ref-type="fig" rid="pone.0210041.g003">Fig 3B</xref>). Even though this was a small difference, an upward bias in the seronegative group could partially mask the magnitude of the bias due to heterogeneous exposure in the overall VE<sub>S</sub> estimates.</p>
                <fig id="pone.0210041.g003" orientation="portrait" position="float">
                  <object-id pub-id-type="doi">10.1371/journal.pone.0210041.g003</object-id>
                  <label>Fig 3</label>
                  <caption>
                    <title>Overall VE<sub>S</sub> and VE<sub>S</sub> with stratification estimated for 1,000 simulations of the baseline scenario for one site.</title>
                    <p>In this scenario, attractiveness of humans is proportional to their body size. VE<sub>S</sub> is calculated with four different methods: VE<sub>S,Cox</sub>, VE<sub>S,IR</sub>, VE<sub>S,CI</sub>, and VE<sub>S,p</sub>. Violin plots on the left panel show the shape of the distribution of VE<sub>S,Cox</sub> estimates. Colored solid lines show the 25, 50, and 75 quantiles for VE<sub>S,Cox</sub>, VE<sub>S,p</sub>, VE<sub>S,IR</sub>, and VE<sub>S,frailty</sub> (gray, blue, red, and green, respectively). Black solid line represents the true PEP = 1—RR<sub>inf|exp</sub> RR<sub>dis|inf</sub> = 0.8. Left panel corresponds to the assumption of viremia in vaccinated individuals as secondary infections. Right panel corresponds to the assumption of viremia in vaccinated individuals as a natural infection.</p>
                  </caption>
                  <graphic xlink:href="pone.0210041.g003"/>
                </fig>
                <p>After reviewing aspects of the simulation model that could have differed between seropositive and seronegative individuals, we hypothesized that a bias away from the null that is distinct from the bias due to heterogeneous exposure occurred as a result of the way in which we simulated viremia trajectories in infections of vaccinated individuals. Because these infections were defined as secondary-like infections with shorter viremia periods (<xref ref-type="supplementary-material" rid="pone.0210041.s003">S1 Fig</xref>), fewer primary infections in the vaccine arm were detected by the RT-PCR than in the placebo arm. This resulted in VE<sub>S</sub> estimates being approximately 0.01 higher on average than they would have been if the viremia trajectories in primary vaccinee infections had been the same as they were in unvaccinated individuals (<xref ref-type="fig" rid="pone.0210041.g003">Fig 3C and 3F</xref>). This bias increased to 0.06 (<xref ref-type="supplementary-material" rid="pone.0210041.s004">S2C and S2F Fig</xref>) in a scenario in which RT-PCR was used up to seven days after symptom onset, in contrast to the baseline of five days. This effect was apparent for seronegative individuals (for whom there were differences in RT-PCR sensitivity between vaccinated and unvaccinated) but not for seropositive individuals (for whom RT-PCR sensitivity was equal for vaccinated and unvaccinated) (<xref ref-type="fig" rid="pone.0210041.g003">Fig 3B and 3C</xref>). We interpret this bias to have occurred because differences in RT-PCR sensitivity among seronegative trial participants resulted in vaccinated individuals being perceived to experience an artificially low number of infections. As expected under this interpretation, this bias disappeared in simulations in which we assumed that RT-PCR sensitivity was the same for vaccinated and unvaccinated individuals (Figs <xref ref-type="fig" rid="pone.0210041.g003">3F</xref> and <xref ref-type="supplementary-material" rid="pone.0210041.s004">S2F</xref>). Furthermore, these individuals were also protected from infection later in the trial, which was perceived to result from vaccination but in reality resulted from heterotypic immunity following natural infection. Assumptions about viremia did not affect VE<sub>S</sub> estimates for the seropositive population (<xref ref-type="fig" rid="pone.0210041.g003">Fig 3B and 3E</xref>), because their viremia curves were the same for vaccinated and unvaccinated individuals.</p>
                <p>Because differential detectability resulted in a bias away from the null under the baseline scenario, it had the effect of slightly reducing our estimate of the extent to which heterogeneous exposure induced bias toward the null. VE<sub>S</sub> estimates from the seropositive group were unaffected by the bias due to differential detectability and, therefore, provided a clearer indication of the extent of bias due to heterogeneous exposure. Across all four measures of VE<sub>S</sub> that we examined, bias was approximately 0.01 more toward the null in the seropositive group than in the trial as a whole (<xref ref-type="fig" rid="pone.0210041.g003">Fig 3F</xref> vs <xref ref-type="fig" rid="pone.0210041.g003">3A</xref>). This relatively small difference between the overall VE<sub>S</sub> estimate and the VE<sub>S</sub> estimate for the seropositive group can be attributed to the majority of trial participants being seropositive (0.6, CI = [0.57,0.63]) and the majority of the cases coming from seropositive individuals (0.66, CI = [0.55, 0.76]). Consequently, the extent to which bias away from the null due to differential detectability counteracts bias toward the null due to heterogeneous exposure would be expected to differ in trials in which the proportion of seropositive trial participants differs from our simulations. In summary, using conventional measures of VE<sub>S</sub> that do not account for these biases (i.e., VE<sub>S,Cox</sub> and VE<sub>S,IR</sub>), analyses of our simulations with PEP = 0.8 resulted in VE<sub>S</sub> estimates that were biased toward the null by approximately 0.09 due to heterogeneous exposure. Estimates of VE<sub>S</sub> were biased away from the null by as much as 0.01 due to differential detectability of primary infections between vaccinated and unvaccinated individuals.</p>
                <p>As one way to place these biases into context, we examined the proportion of simulated trials in which the vaccine would not have been licensed on the basis of the VE<sub>S</sub> point estimate falling below the minimum product profile (MPP). For an MPP of 0.3, this probability depended on the VE<sub>S</sub> measure used at different values of PEP. This probability was always lower for the VE<sub>S,p</sub> measure, compared to the other three measures used (<xref ref-type="fig" rid="pone.0210041.g004">Fig 4</xref>). For instance, for PEP = 0.4, the vaccine would not have been licensed in nearly 40% of simulated trials on the basis of the point estimates of VE<sub>S,Cox</sub>, VE<sub>S,frailty</sub>, and VE<sub>S,IR</sub>. It would not have been licensed in almost all simulated trials if the lower bound of the confidence interval of the VE<sub>S</sub> estimates were used as a criterion for licensure. For PEP = 0.4, the probability of a vaccine not being licensed on the basis of the point estimate of VE<sub>S,p</sub> was only around 0.2, and around 0.8 when based on the lower bound of the confidence interval. Across these and other instances, there was a lower probability of rejecting a vaccine with PEP exceeding MPP whenever PEP was farther away from MEP and when bias toward the null was less severe.</p>
                <fig id="pone.0210041.g004" orientation="portrait" position="float">
                  <object-id pub-id-type="doi">10.1371/journal.pone.0210041.g004</object-id>
                  <label>Fig 4</label>
                  <caption>
                    <title>Probability of not licensing a vaccine with MPP = 0.3 at different input PEP values.</title>
                    <p>Solid lines represent the probability of rejection calculated as the proportion of simulations where the lower bound of the confidence interval of VE<sub>S</sub> was below MPP. Dotted lines represent the probability of rejection calculated as the proportion of simulations where the mean estimate of VE<sub>S</sub> was below MPP.</p>
                  </caption>
                  <graphic xlink:href="pone.0210041.g004"/>
                </fig>
              </sec>
              <sec id="sec018">
                <title>2. Effects of heterogeneous exposure due to heterogeneous biting</title>
                <p>The scenario with homogeneous hazard of exposure was associated with less bias toward the null compared to the three scenarios that allowed for some form of heterogeneous hazard of exposure (<xref ref-type="fig" rid="pone.0210041.g005">Fig 5A</xref> compared with <xref ref-type="fig" rid="pone.0210041.g005">Fig 5B–5D</xref>). When the hazard of exposure was homogeneous, VE<sub>S,p</sub> and VE<sub>S,frailty</sub> were approximately equal to PEP (VE<sub>S,p</sub> = 0.8, VE<sub>S,frailty</sub> = 0.79), and the other two measures slightly underestimated it (VE<sub>S,Cox</sub> = 0.77, VE<sub>S,IR</sub> = 0.77) (<xref ref-type="fig" rid="pone.0210041.g005">Fig 5A</xref>). As in the baseline scenario described above, overall estimates of VE<sub>S</sub> reflect a combination of distinct VE<sub>S</sub> estimates for the seropositive and seronegative groups, due to a bias away from the null resulting from differential detectability of primary infections among vaccinated and unvaccinated individuals. Among seropositive individuals, VE<sub>S,p</sub> was the only measure that appeared to be unbiased (blue in <xref ref-type="fig" rid="pone.0210041.g006">Fig 6A</xref>). The other three measures exhibited some bias toward the null (red, gray, green in <xref ref-type="fig" rid="pone.0210041.g006">Fig 6A</xref>), because a homogeneous hazard of exposure still results in some degree of heterogeneity in the numbers of exposures that individuals experience (<xref ref-type="supplementary-material" rid="pone.0210041.s006">S4 Fig</xref>). Among seronegative individuals in the vaccinated group, the downward bias of heterogeneous exposure canceled out with the upward bias of lower detectability of primary infections and VE<sub>S,Cox</sub> and VE<sub>S</sub>,<sub>IR</sub> showed unbiased estimates of VE<sub>S</sub>, while VE<sub>S,p</sub> and VE<sub>S,frailty</sub> displayed bias away from the null for this group (<xref ref-type="fig" rid="pone.0210041.g006">Fig 6E</xref>).</p>
                <fig id="pone.0210041.g005" orientation="portrait" position="float">
                  <object-id pub-id-type="doi">10.1371/journal.pone.0210041.g005</object-id>
                  <label>Fig 5</label>
                  <caption>
                    <title>Vaccine efficacy in four scenarios about heterogeneous exposure to DENV for seropositive and seronegative individuals.</title>
                    <p>Violin plots show the shape of the distribution of VE<sub>S,Cox</sub> estimates. The colored solid lines show the 25, 50, and 75 quantiles for VE<sub>S,Cox</sub>, VE<sub>S,p</sub>, VE<sub>S,IR</sub>, and VE<sub>S,frailty</sub> (gray, blue, red, and green, respectively). Black solid line represents the individual input of vaccine efficacy: VE = 1 –PEP = 1—RR<sub>inf|exp</sub> RR<sub>dis|inf</sub> = 0.8. The left panel corresponds to VE<sub>S</sub> in seropositives and the right panel corresponds to the VE<sub>S</sub> in seronegatives.</p>
                  </caption>
                  <graphic xlink:href="pone.0210041.g005"/>
                </fig>
                <fig id="pone.0210041.g006" orientation="portrait" position="float">
                  <object-id pub-id-type="doi">10.1371/journal.pone.0210041.g006</object-id>
                  <label>Fig 6</label>
                  <caption>
                    <title>Vaccine efficacy in four scenarios about heterogeneous exposure to DENV for seropositive and seronegative individuals.</title>
                    <p>Violin plots show the shape of the distribution of VE<sub>S,Cox</sub> estimates. The colored solid lines show the 25, 50, and 75 quantiles for VE<sub>S,Cox</sub>, VE<sub>S,p</sub>, VE<sub>S,IR</sub>, and VE<sub>S,frailty</sub> (gray, blue, red, and green, respectively). Black solid line represents the individual input of vaccine efficacy: VE = 1 –PEP = 1—RR<sub>inf|exp</sub> RR<sub>dis|inf</sub> = 0.8. The left panel corresponds to VE<sub>S</sub> in seropositives and the right panel corresponds to the VE<sub>S</sub> in seronegatives.</p>
                  </caption>
                  <graphic xlink:href="pone.0210041.g006"/>
                </fig>
                <p>The scenarios with heterogeneous hazard of exposure resulted in a larger bias toward the null when using VE<sub>S,Cox</sub>, VE<sub>S,IR</sub>, and VE<sub>S,frailty</sub> than when using VE<sub>S,p</sub> (blue closer to PEP than gray, red, or green in <xref ref-type="fig" rid="pone.0210041.g005">Fig 5B–5D</xref>). These estimates were all within approximately 0.01 of each other under all three scenarios that allowed for heterogeneous attractiveness of humans to mosquitoes (right three columns in <xref ref-type="supplementary-material" rid="pone.0210041.s007">S5 Fig</xref>), as opposed to a difference of approximately 0.05 between the homogeneous scenario and each of the three heterogeneous scenarios (left three columns in <xref ref-type="supplementary-material" rid="pone.0210041.s007">S5 Fig</xref>). This indicates that a substantial degree of heterogeneity in exposure derives from spatial heterogeneity in mosquito density among different houses and heterogeneity in how individual humans sample that heterogeneity through their movement patterns, whereas relatively little derives from heterogeneous blood feeding within a single house. Examination of the distribution of the number of exposures experienced by trial participants further supports this conclusion, with higher variance in the number of exposures under the three heterogeneous scenarios than under the homogeneous scenario (<xref ref-type="supplementary-material" rid="pone.0210041.s006">S4 Fig</xref>).</p>
              </sec>
              <sec id="sec019">
                <title>3. Effect of increased heterogeneity of exposure due to high transmission intensity</title>
                <p>Higher transmission intensity increased the bias in VE<sub>S</sub> estimates even further toward the null because of a higher chance of repeated exposure in the population at risk, which increased heterogeneity in the number of exposures. This increased heterogeneity also affected the scenario with homogeneous hazard of infection (<xref ref-type="fig" rid="pone.0210041.g007">Fig 7A</xref>), because homogeneity in the hazard of exposure does not ensure homogeneity in the number of exposures that individuals experience during the trial. Some individuals in this scenario were exposed up to five times during the trial (<xref ref-type="supplementary-material" rid="pone.0210041.s008">S6 Fig</xref>), compared to a maximum of three exposures under the baseline transmission intensity assumptions (<xref ref-type="supplementary-material" rid="pone.0210041.s006">S4 Fig</xref>). Under the homogeneous hazard scenario, the frailty model did a relatively good job of reducing bias toward the null (VE<sub>S,frailty</sub> = 0.77, compared with VE<sub>S,Cox</sub> = 0.64, VE<sub>S,IR</sub> = 0.64), but it was less successful at doing so under the three heterogeneous hazard scenarios (VE<sub>S,frailty</sub> = 0.69, compared with VE<sub>S,Cox</sub> = 0.66, VE<sub>S,IR</sub> = 0.66) (<xref ref-type="fig" rid="pone.0210041.g007">Fig 7B–7D</xref>). Accounting for exposure with VE<sub>S,p</sub> resulted in unbiased estimates.</p>
                <fig id="pone.0210041.g007" orientation="portrait" position="float">
                  <object-id pub-id-type="doi">10.1371/journal.pone.0210041.g007</object-id>
                  <label>Fig 7</label>
                  <caption>
                    <title>Overall VE<sub>S</sub> estimates from 1,000 simulations of each setting with different assumptions about heterogeneous exposure in a high-intensity setting.</title>
                    <p>Sample size was adjusted to 800 participants to achieve 90% statistical power in a higher transmission setting. Each row represents an assumption about heterogeneous exposure to DENV: homogeneous hazard of exposure, constant attractiveness of humans, attractiveness of humans based on body size, and attractiveness of humans based on a gamma distribution (shape = 1.43 and scale = 1). VE<sub>S</sub> is calculated with four different methods: VE<sub>S,Cox</sub>, VE<sub>S,IR</sub>, VE<sub>S,CI</sub>, and VE<sub>S,p</sub>. Violin plots on the left panel show the shape of the distribution of VE<sub>S,Cox</sub> estimates. Colored solid lines show the 25, 50, and 75 quantiles for VE<sub>S,Cox</sub>, VE<sub>S,p</sub>, VE<sub>S,IR</sub>, and VE<sub>S,frailty</sub> (gray, blue, red, and green, respectively). Black solid line represents the true PEP = 1—RR<sub>inf|exp</sub> RR<sub>dis|inf</sub> = 0.8. Right panel corresponds to the number of cases captured in the trial.</p>
                  </caption>
                  <graphic xlink:href="pone.0210041.g007"/>
                </fig>
              </sec>
            </sec>
            <sec sec-type="conclusions" id="sec020">
              <title>Discussion</title>
              <p>Our results indicate that, under the assumption of a leaky vaccine (i.e., provides partial protection to all vaccinated individuals), VE<sub>S</sub> is consistently underestimated by standard measures that do not account for the repeated, heterogeneous nature of DENV exposure. For instance, heterogeneity in exposure violates an assumption required by the Cox model to ensure unbiased estimates of VE<sub>S</sub> [<xref rid="pone.0210041.ref022" ref-type="bibr">22</xref>]. Heterogeneous exposure has the effect of reducing efficacy because some individuals are highly protected from infection in both arms of the study, which makes the placebo arm of the study more similar to the vaccine arm. Under the default assumptions and scenarios that we examined, we observed that the extent of bias toward the null as a result of heterogeneous exposure could be as great as 21% of the value of simulated PEP, depending on the extent to which the vaccine protects against infection or disease. Depending on the simulated value of PEP and how close it was to MPP, we found that different methods for estimating VE<sub>S</sub> have implications for the possibility of not licensing a vaccine that has desirable properties but is not perceived as such due to bias from heterogeneous exposure.</p>
              <p>One possibility for mitigating bias due to heterogeneous exposure that we examined was incorporating a frailty expression, which accounts for unmeasured heterogeneity as a random effect [<xref rid="pone.0210041.ref021" ref-type="bibr">21</xref>], into our Cox survival analysis of simulated trial data. This step did help reduce VE<sub>S</sub> bias, particularly under scenarios in which heterogeneity was more extreme. Although our results indicate that incorporation of a frailty term into estimation of VE<sub>S</sub> from dengue vaccine trial data could help reduce bias toward the null, a caveat is that biased estimates of VE<sub>S</sub> can still be obtained when the frailty distribution is not accurately specified [<xref rid="pone.0210041.ref021" ref-type="bibr">21</xref>]. Also, at high degrees of censoring, non-identifiability of the model parameters can be an issue with frailty models [<xref rid="pone.0210041.ref021" ref-type="bibr">21</xref>].</p>
              <p>Another possibility for mitigating bias due to heterogeneous exposure is to incorporate information about the number of exposures in each trial arm. This approach successfully eliminated bias due to heterogeneous exposure in our simulations. A disadvantage, however, is that additional information pertinent to the number of exposures in each trial arm must be collected. In a real trial, doing so would amount to obtaining estimates of the total number of bites by infectious mosquitoes on all individuals in each trial arm. Even as an average across many individuals in a trial arm, estimating entomological risk of DENV infection is not straightforward [<xref rid="pone.0210041.ref059" ref-type="bibr">59</xref>]. Challenges to doing so include significant spatiotemporal heterogeneity in DENV transmission activity [<xref rid="pone.0210041.ref007" ref-type="bibr">7</xref>], shifting hotspots of mosquito density over timescales shorter than a trial [<xref rid="pone.0210041.ref015" ref-type="bibr">15</xref>], and the fact that individuals are subject to mosquito bites and DENV exposure at the numerous locations they visit during their daily routines [<xref rid="pone.0210041.ref060" ref-type="bibr">60</xref>]. Unfortunately, these are precisely the forms of heterogeneity that our results indicate contribute most to bias in VE<sub>S</sub> estimates, rendering VE<sub>S,p</sub> an ideal, but impractical, solution to mitigate bias due to heterogeneous exposure.</p>
              <p>We also found an unexpected source of bias for seronegative individuals. This bias comes from our assumption of shorter viremia periods in primary infections for vaccinated compared to unvaccinated individuals. This assumption resulted in fewer detected cases between follow-up visits in the vaccine arm than in the placebo arm. As a consequence, estimates of VE<sub>S</sub> in the seronegative group were biased away from the null. This bias was relatively small when the RT-PCR was used up to five days after symptom onset, as advised by the Centers for Disease Control and Prevention [<xref rid="pone.0210041.ref038" ref-type="bibr">38</xref>]. Not adhering to these guidelines could, however, result in larger bias away from the null, which we observed when we allowed use of RT-PCR up to seven days after symptom onset. Ignoring this type of bias could result in reducing the magnitude of the bias toward the null from heterogeneous exposure. Doing so may be acceptable from the perspective of estimating overall VE<sub>S</sub>, but it has the potential to bias estimates of VE<sub>S</sub> for seronegatives above that of seropositives. For biological reasons [<xref rid="pone.0210041.ref061" ref-type="bibr">61</xref>], estimates for Dengvaxia indicate that VE<sub>S</sub> is higher for seropositives than seronegatives [<xref rid="pone.0210041.ref029" ref-type="bibr">29</xref>]. If analyses of Dengvaxia trial data are subject to this bias from differential detectability, that would indicate that the estimated difference in VE<sub>S</sub> between seropositives and seronegatives could be somewhat greater than currently thought.</p>
              <p>There are also sources of bias other than heterogeneous exposure and differential detectability that could manifest in dengue vaccine trials. For instance, infections among trial participants that go undetected could result in bias toward the null. This could occur if analyses of symptomatic endpoints fail to consider that unobserved infections in the placebo arm differentially reduce person-time at risk, increasing the apparent similarity between outcomes in vaccine and placebo arms [<xref rid="pone.0210041.ref062" ref-type="bibr">62</xref>]. This effect may have been moderated in our analyses because conditions that promote it—protection deriving from blocking infection rather than ameliorating disease, high baseline hazard—were not in effect to a large degree. Nonetheless, undetected DENV infections are common [<xref rid="pone.0210041.ref063" ref-type="bibr">63</xref>] and can cause other problems for the interpretation of dengue vaccine trial data [<xref rid="pone.0210041.ref064" ref-type="bibr">64</xref>]. Heterogeneity in susceptibility is a related source of bias that causes bias toward the null for reasons similar to why unobserved infections do [<xref rid="pone.0210041.ref065" ref-type="bibr">65</xref>]. Although pre-enrollment serological testing could be used to classify individuals as seropositive or seronegative for any dengue vaccine trial, it is likely that the serotype(s) to which an individual is susceptible would be undefined, which could be considered a potential source of unmeasured heterogeneity in susceptibility.</p>
              <p>Recent decades have seen great elaboration of theory for vaccine trial design and analysis [<xref rid="pone.0210041.ref019" ref-type="bibr">19</xref>], which has increasingly embraced heterogeneity in data-generating processes such as exposure. This growing body of literature has resulted in a number of principles about potential sources of bias in VE<sub>S</sub> estimation, highlighted through simulation experiments that have tended to make use of relatively simple models [<xref rid="pone.0210041.ref066" ref-type="bibr">66</xref>]. Because our primary goal in this study was to quantify the extent of a known bias for a specific disease, we opted for an agent-based model that uses highly detailed data to realistically simulate effects of heterogeneous exposure. In addition to achieving this explicit goal of our study, we uncovered an unexpected source of bias that could have implications for interpretation of Dengvaxia trial data. This discovery emerged from our analyses as a result of including detail in model structure beyond what was minimally necessary to meet our primary goal of quantifying bias due to heterogeneous exposure. This work adds to a growing list of applications of dynamic transmission models to planning for dengue vaccine trials (this study), interpreting their results [<xref rid="pone.0210041.ref035" ref-type="bibr">35</xref>,<xref rid="pone.0210041.ref061" ref-type="bibr">61</xref>], and making projections of their impacts when deployed at the population level [<xref rid="pone.0210041.ref042" ref-type="bibr">42</xref>,<xref rid="pone.0210041.ref046" ref-type="bibr">46</xref>,<xref rid="pone.0210041.ref047" ref-type="bibr">47</xref>,<xref rid="pone.0210041.ref061" ref-type="bibr">61</xref>].</p>
            </sec>
            <sec sec-type="supplementary-material" id="sec021">
              <title>Supporting information</title>
              <supplementary-material content-type="local-data" id="pone.0210041.s001">
                <label>S1 Text</label>
                <caption>
                  <title>Statistical estimation of sample size.</title>
                  <p>(DOCX)</p>
                </caption>
                <media xlink:href="pone.0210041.s001.docx">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material content-type="local-data" id="pone.0210041.s002">
                <label>S2 Text</label>
                <caption>
                  <title>Agent-based model of dengue virus transmission.</title>
                  <p>(DOCX)</p>
                </caption>
                <media xlink:href="pone.0210041.s002.docx">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material content-type="local-data" id="pone.0210041.s003">
                <label>S1 Fig</label>
                <caption>
                  <title>Sensitivity as a function of time since symptom onset for primary and post-primary DENV-infected individuals given a limit of detection of 10 cDNA copies/mL.</title>
                  <p>Dots represent the sensitivity curves obtained from 3,000 simulations of viremia. Solid lines represent the fitted curves described in <xref ref-type="disp-formula" rid="pone.0210041.e001">Eq 1</xref>. For primary infections, <inline-formula id="pone.0210041.e013"><alternatives><graphic xlink:href="pone.0210041.e013.jpg" id="pone.0210041.e013g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M13"><mml:msubsup><mml:mrow><mml:mi>β</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msubsup><mml:mi> </mml:mi><mml:mo>=</mml:mo><mml:mi> </mml:mi><mml:mn>13.18506</mml:mn></mml:math></alternatives></inline-formula> and <inline-formula id="pone.0210041.e014"><alternatives><graphic xlink:href="pone.0210041.e014.jpg" id="pone.0210041.e014g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M14"><mml:msubsup><mml:mrow><mml:mi>β</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msubsup><mml:mi> </mml:mi><mml:mo>=</mml:mo><mml:mi> </mml:mi><mml:mo>-</mml:mo><mml:mn>1.665468</mml:mn></mml:math></alternatives></inline-formula>. For post-primary infections, <inline-formula id="pone.0210041.e015"><alternatives><graphic xlink:href="pone.0210041.e015.jpg" id="pone.0210041.e015g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M15"><mml:msubsup><mml:mrow><mml:mi>β</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup><mml:mi> </mml:mi><mml:mo>=</mml:mo><mml:mi> </mml:mi><mml:mn>6.834631</mml:mn></mml:math></alternatives></inline-formula> and <inline-formula id="pone.0210041.e016"><alternatives><graphic xlink:href="pone.0210041.e016.jpg" id="pone.0210041.e016g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M16"><mml:msubsup><mml:mrow><mml:mi>β</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup><mml:mi> </mml:mi><mml:mo>=</mml:mo><mml:mi> </mml:mi><mml:mo>-</mml:mo><mml:mn>1.166282</mml:mn></mml:math></alternatives></inline-formula>.</p>
                  <p>(PDF)</p>
                </caption>
                <media xlink:href="pone.0210041.s003.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material content-type="local-data" id="pone.0210041.s004">
                <label>S2 Fig</label>
                <caption>
                  <title>Overall VE<sub>S</sub> and VE<sub>S</sub> with stratification estimated for 1,000 simulations of the baseline scenario for one site with RT-PCR up to 7 days after symptom onset.</title>
                  <p>Attractiveness of humans is proportional to their body size. VE<sub>S</sub> is calculated with four different methods: VE<sub>S,Cox</sub>, VE<sub>S,p</sub>, VE<sub>S,IR</sub>, and VE<sub>S,frailty</sub> (gray, blue, red, and green, respectively). Left panel shows results under the assumption that viremia in vaccinated individuals is similar to that in secondary infections. In the right panel, viremia in vaccinees is the same as a natural infection. Violin plots show the shape of the distribution of VE<sub>S,Cox</sub> estimates. Colored solid lines show the 25, 50, and 75 quantiles for VE<sub>S</sub>. Black solid line represents the individual input of PEP = 1—RR<sub>inf|exp</sub> RR<sub>dis|inf</sub> = 0.8.</p>
                  <p>(EPS)</p>
                </caption>
                <media xlink:href="pone.0210041.s004.eps">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material content-type="local-data" id="pone.0210041.s005">
                <label>S3 Fig</label>
                <caption>
                  <title>Sensitivity of overall VE<sub>S</sub> to changes in the proportion of protection from infection.</title>
                  <p>Each panel shows VE<sub>S</sub> estimates across different values of the parameter p. Dots show the estimates for each of the four VE<sub>S</sub> measures: VE<sub>S,Cox</sub>, VE<sub>S,p</sub>, VE<sub>S,IR</sub>, and VE<sub>S,frailty</sub>. The black line shows the regression obtained with a generalized additive model and the dark-gray band shows the 95% confidence interval. In all scenarios, PEP is represented by the black dotted line and is defined as PEP = 1 –RR<sub>inf|exp</sub> RR<sub>dis|inf</sub> = 0.8. The proportion of protection from infection, p, is defined such that RR<sub>inf</sub> = (1 –PEP)<sup>ρ</sup><sub>,</sub> and RR<sub>dis|inf</sub> = (1 –PEP)<sup>1 –ρ</sup><sub>.</sub></p>
                  <p>(EPS)</p>
                </caption>
                <media xlink:href="pone.0210041.s005.eps">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material content-type="local-data" id="pone.0210041.s006">
                <label>S4 Fig</label>
                <caption>
                  <title>Distribution of exposures within the vaccine group of the trial for each of four assumptions of heterogeneity of exposure.</title>
                  <p>The height of the bars represents the relative frequency of the number of exposures in the vaccine arm for a specific realization of the virtual trial. The four simulations used the same random number seed to increase comparability among simulations.</p>
                  <p>(EPS)</p>
                </caption>
                <media xlink:href="pone.0210041.s006.eps">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material content-type="local-data" id="pone.0210041.s007">
                <label>S5 Fig</label>
                <caption>
                  <title>Pairwise difference of VE<sub>S,Cox</sub> between different scenarios about heterogeneous exposure.</title>
                  <p>Each scenario was simulated 1,000 times with the same sequence of random number seeds to minimize differences caused by stochastic effects.</p>
                  <p>(EPS)</p>
                </caption>
                <media xlink:href="pone.0210041.s007.eps">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material content-type="local-data" id="pone.0210041.s008">
                <label>S6 Fig</label>
                <caption>
                  <title>Distribution of exposures within the vaccine arm of the trial under different scenarios about heterogeneous exposure with high transmission intensity.</title>
                  <p>The height of the bars represents the relative frequency of the number of exposures in the vaccine arm for a specific realization of the virtual trial. The four simulations used the same random number seed to increase comparability among simulations.</p>
                  <p>(EPS)</p>
                </caption>
                <media xlink:href="pone.0210041.s008.eps">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <ref-list>
              <title>References</title>
              <ref id="pone.0210041.ref001">
                <label>1</label>
                <mixed-citation publication-type="journal"><name><surname>Bhatt</surname><given-names>S</given-names></name>, <name><surname>Gething</surname><given-names>PW</given-names></name>, <name><surname>Brady</surname><given-names>OJ</given-names></name>, <name><surname>Messina</surname><given-names>JP</given-names></name>, <name><surname>Farlow</surname><given-names>AW</given-names></name>, <name><surname>Moyes</surname><given-names>CL</given-names></name>, <etal>et al</etal><article-title>The global distribution and burden of dengue</article-title>. <source>Nature</source>. Nature Publishing Group; <year>2013</year>;<volume>496</volume>: <fpage>504</fpage><pub-id pub-id-type="doi">10.1038/nature12060</pub-id><?supplied-pmid 23563266?><pub-id pub-id-type="pmid">23563266</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0210041.ref002">
                <label>2</label>
                <mixed-citation publication-type="journal"><name><surname>Gessner</surname><given-names>BD</given-names></name>, <name><surname>Halsey</surname><given-names>N</given-names></name>. <article-title>Dengue vaccine safety signal: Immune enhancement, waning immunity, or chance occurrence?</article-title><source>Vaccine</source>. Elsevier; <year>2017</year>;<volume>35</volume>: <fpage>3452</fpage>–<lpage>3456</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2017.05.003</pub-id>
<?supplied-pmid 28528764?><pub-id pub-id-type="pmid">28528764</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0210041.ref003">
                <label>3</label>
                <mixed-citation publication-type="journal"><name><surname>Vannice</surname><given-names>KS</given-names></name>, <name><surname>Durbin</surname><given-names>A</given-names></name>, <name><surname>Hombach</surname><given-names>J</given-names></name>. <article-title>Status of vaccine research and development of vaccines for dengue</article-title>. <source>Vaccine</source>. <year>2016</year>;<volume>34</volume>: <fpage>2934</fpage>–<lpage>2938</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2015.12.073</pub-id>
<?supplied-pmid 26973072?><pub-id pub-id-type="pmid">26973072</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0210041.ref004">
                <label>4</label>
                <mixed-citation publication-type="journal"><name><surname>Precioso</surname><given-names>AR</given-names></name>, <name><surname>Palacios</surname><given-names>R</given-names></name>, <name><surname>Thomé</surname><given-names>B</given-names></name>, <name><surname>Mondini</surname><given-names>G</given-names></name>, <name><surname>Braga</surname><given-names>P</given-names></name>, <name><surname>Kalil</surname><given-names>J</given-names></name>. <article-title>Clinical evaluation strategies for a live attenuated tetravalent dengue vaccine</article-title>. <source>Vaccine</source>. <year>2015</year>;<volume>33</volume>: <fpage>7121</fpage>–<lpage>7125</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2015.09.105</pub-id>
<?supplied-pmid 26458796?><pub-id pub-id-type="pmid">26458796</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0210041.ref005">
                <label>5</label>
                <mixed-citation publication-type="journal"><name><surname>Osorio</surname><given-names>JE</given-names></name>, <name><surname>Partidos</surname><given-names>CD</given-names></name>, <name><surname>Wallace</surname><given-names>D</given-names></name>, <name><surname>Stinchcomb</surname><given-names>DT</given-names></name>. <article-title>Development of a recombinant, chimeric tetravalent dengue vaccine candidate</article-title>. <source>Vaccine</source>. <year>2015</year>;<volume>33</volume>: <fpage>7112</fpage>–<lpage>7120</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2015.11.022</pub-id>
<?supplied-pmid 26585500?><pub-id pub-id-type="pmid">26585500</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0210041.ref006">
                <label>6</label>
                <mixed-citation publication-type="other">World Health Organization. WHO vaccine pipeline tracker [Internet]. 2018 [cited 1 Aug 2018]. Available: <ext-link ext-link-type="uri" xlink:href="http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/">http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/</ext-link></mixed-citation>
              </ref>
              <ref id="pone.0210041.ref007">
                <label>7</label>
                <mixed-citation publication-type="journal"><name><surname>Mammen</surname><given-names>MP</given-names></name>, <name><surname>Pimgate</surname><given-names>C</given-names></name>, <name><surname>Koenraadt</surname><given-names>CJM</given-names></name>, <name><surname>Rothman</surname><given-names>AL</given-names></name>, <name><surname>Aldstadt</surname><given-names>J</given-names></name>, <name><surname>Nisalak</surname><given-names>A</given-names></name>, <etal>et al</etal><article-title>Spatial and temporal clustering of dengue virus transmission in Thai villages</article-title>. <source>PLoS Med</source>. <year>2008</year>;<volume>5</volume>: <fpage>e205</fpage><pub-id pub-id-type="doi">10.1371/journal.pmed.0050205</pub-id><?supplied-pmid 18986209?><pub-id pub-id-type="pmid">18986209</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0210041.ref008">
                <label>8</label>
                <mixed-citation publication-type="journal"><name><surname>Salje</surname><given-names>H</given-names></name>, <name><surname>Lessler</surname><given-names>J</given-names></name>, <name><surname>Maljkovic Berry</surname><given-names>I</given-names></name>, <name><surname>Melendrez</surname><given-names>MC</given-names></name>, <name><surname>Endy</surname><given-names>T</given-names></name>, <name><surname>Kalayanarooj</surname><given-names>S</given-names></name>, <etal>et al</etal><article-title>Dengue diversity across spatial and temporal scales: Local structure and the effect of host population size</article-title>. <source>Science (80-)</source>. American Association for the Advancement of Science; <year>2017</year>;<volume>355</volume>: <fpage>1302</fpage>–<lpage>1306</lpage>. <pub-id pub-id-type="doi">10.1126/science.aaj9384</pub-id>
<?supplied-pmid 28336667?><pub-id pub-id-type="pmid">28336667</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0210041.ref009">
                <label>9</label>
                <mixed-citation publication-type="journal"><name><surname>Salje</surname><given-names>H</given-names></name>, <name><surname>Lessler</surname><given-names>J</given-names></name>, <name><surname>Paul</surname><given-names>KK</given-names></name>, <name><surname>Azman</surname><given-names>AS</given-names></name>, <name><surname>Rahman</surname><given-names>MW</given-names></name>, <name><surname>Rahman</surname><given-names>MW</given-names></name>, <etal>et al</etal><article-title>How social structures, space, and behaviors shape the spread of infectious diseases using chikungunya as a case study</article-title>. <source>Proc Natl Acad Sci</source>. National Academy of Sciences; <year>2016</year>;<volume>113</volume>: <fpage>13420</fpage>–<lpage>13425</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1611391113</pub-id>
<?supplied-pmid 27821727?><pub-id pub-id-type="pmid">27821727</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0210041.ref010">
                <label>10</label>
                <mixed-citation publication-type="journal"><name><surname>Perkins</surname><given-names>A</given-names></name>, <name><surname>Rodriguez-Barraquer</surname><given-names>I</given-names></name>, <name><surname>Manore</surname><given-names>C</given-names></name>, <name><surname>Siraj</surname><given-names>A</given-names></name>, <name><surname>Espana</surname><given-names>G</given-names></name>, <name><surname>Barker</surname><given-names>C</given-names></name>, <etal>et al</etal><article-title>What lies beneath: a spatial mosaic of Zika virus transmission in the 2015–2016 epidemic in Colombia</article-title>. <source>bioRxiv</source>. Cold Spring Harbor Laboratory; <year>2018</year>; <pub-id pub-id-type="doi">10.1101/276006</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0210041.ref011">
                <label>11</label>
                <mixed-citation publication-type="journal"><name><surname>Liebman</surname><given-names>KA</given-names></name>, <name><surname>Stoddard</surname><given-names>ST</given-names></name>, <name><surname>Reiner</surname><given-names>RC</given-names></name>, <name><surname>Perkins</surname><given-names>TA</given-names></name>, <name><surname>Astete</surname><given-names>H</given-names></name>, <name><surname>Sihuincha</surname><given-names>M</given-names></name>, <etal>et al</etal><article-title>Determinants of Heterogeneous Blood Feeding Patterns by Aedes aegypti in Iquitos, Peru</article-title>. <name><surname>Barrera</surname><given-names>R</given-names></name>, editor. <source>PLoS Negl Trop Dis</source>. Public Library of Science; <year>2014</year>;<volume>8</volume>: <fpage>1</fpage>–<lpage>10</lpage>. <pub-id pub-id-type="doi">10.1371/journal.pntd.0002702</pub-id>
<?supplied-pmid 24551262?><pub-id pub-id-type="pmid">24551262</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0210041.ref012">
                <label>12</label>
                <mixed-citation publication-type="journal"><name><surname>De Benedictis</surname><given-names>J</given-names></name>, <name><surname>Chow-Shaffer</surname><given-names>E</given-names></name>, <name><surname>Costero</surname><given-names>A</given-names></name>, <name><surname>Clark</surname><given-names>GG</given-names></name>, <name><surname>Edman</surname><given-names>JD</given-names></name>, <name><surname>Scott</surname><given-names>TW</given-names></name>. <article-title>Identification of the people from whom engorged Aedes aegypti took blood meals in Florida, Puerto Rico, using polymerase chain reaction-based DNA profiling</article-title>. <source>Am J Trop Med Hyg</source>. <year>2003</year>;<volume>68</volume>: <fpage>437</fpage>–<lpage>446</lpage>. <pub-id pub-id-type="doi">10.4269/ajtmh.2003.68.437</pub-id>
<?supplied-pmid 12875293?><pub-id pub-id-type="pmid">12875293</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0210041.ref013">
                <label>13</label>
                <mixed-citation publication-type="journal"><name><surname>Woolhouse</surname><given-names>ME</given-names></name>, <name><surname>Dye</surname><given-names>C</given-names></name>, <name><surname>Etard</surname><given-names>JF</given-names></name>, <name><surname>Smith</surname><given-names>T</given-names></name>, <name><surname>Charlwood</surname><given-names>JD</given-names></name>, <name><surname>Garnett</surname><given-names>GP</given-names></name>, <etal>et al</etal><article-title>Heterogeneities in the transmission of infectious agents: implications for the design of control programs</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>1997</year>;<volume>94</volume>: <fpage>338</fpage>–<lpage>42</lpage>. Available: <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/8990210">http://www.ncbi.nlm.nih.gov/pubmed/8990210</ext-link>
<?supplied-pmid 8990210?><pub-id pub-id-type="pmid">8990210</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0210041.ref014">
                <label>14</label>
                <mixed-citation publication-type="journal"><name><surname>Perkins</surname><given-names>TA</given-names></name>, <name><surname>Scott</surname><given-names>TW</given-names></name>, <name><surname>Le Menach</surname><given-names>A</given-names></name>, <name><surname>Smith</surname><given-names>DL</given-names></name>. <article-title>Heterogeneity, Mixing, and the Spatial Scales of Mosquito-Borne Pathogen Transmission</article-title>. <name><surname>Salathé</surname><given-names>M</given-names></name>, editor. <source>PLoS Comput Biol</source>. Public Library of Science; <year>2013</year>;<volume>9</volume>: <fpage>1</fpage>–<lpage>16</lpage>. <pub-id pub-id-type="doi">10.1371/journal.pcbi.1003327</pub-id>
<?supplied-pmid 24348223?><pub-id pub-id-type="pmid">24348223</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0210041.ref015">
                <label>15</label>
                <mixed-citation publication-type="journal"><name><surname>LaCon</surname><given-names>G</given-names></name>, <name><surname>Morrison</surname><given-names>AC</given-names></name>, <name><surname>Astete</surname><given-names>H</given-names></name>, <name><surname>Stoddard</surname><given-names>ST</given-names></name>, <name><surname>Paz-Soldan</surname><given-names>VA</given-names></name>, <name><surname>Elder</surname><given-names>JP</given-names></name>, <etal>et al</etal><article-title>Shifting Patterns of Aedes aegypti Fine Scale Spatial Clustering in Iquitos, Peru</article-title>. <source>PLoS Negl Trop Dis</source>. Public Library of Science; <year>2014</year>;<volume>8</volume>: <fpage>1</fpage>–<lpage>13</lpage>. <pub-id pub-id-type="doi">10.1371/journal.pntd.0003038</pub-id>
<?supplied-pmid 25102062?><pub-id pub-id-type="pmid">25102062</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0210041.ref016">
                <label>16</label>
                <mixed-citation publication-type="journal"><name><surname>Perkins</surname><given-names>TA</given-names></name>, <name><surname>Garcia</surname><given-names>AJ</given-names></name>, <name><surname>Paz-Soldán</surname><given-names>VA</given-names></name>, <name><surname>Stoddard</surname><given-names>ST</given-names></name>, <name><surname>Reiner</surname><given-names>RC</given-names></name>, <name><surname>Vazquez-Prokopec</surname><given-names>G</given-names></name>, <etal>et al</etal><article-title>Theory and data for simulating fine-scale human movement in an urban environment</article-title>. <source>J R Soc Interface</source>. The Royal Society; <year>2014</year>;<volume>11</volume><pub-id pub-id-type="doi">10.1098/rsif.2014.0642</pub-id><?supplied-pmid 25142528?><pub-id pub-id-type="pmid">25142528</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0210041.ref017">
                <label>17</label>
                <mixed-citation publication-type="journal"><name><surname>Perkins</surname><given-names>TA</given-names></name>, <name><surname>Paz-Soldan</surname><given-names>VA</given-names></name>, <name><surname>Stoddard</surname><given-names>ST</given-names></name>, <name><surname>Morrison</surname><given-names>AC</given-names></name>, <name><surname>Forshey</surname><given-names>BM</given-names></name>, <name><surname>Long</surname><given-names>KC</given-names></name>, <etal>et al</etal><article-title>Calling in sick: impacts of fever on intra-urban human mobility</article-title>. <source>Proc R Soc London B Biol Sci</source>. The Royal Society; <year>2016</year>;<volume>283</volume><pub-id pub-id-type="doi">10.1098/rspb.2016.0390</pub-id><?supplied-pmid 27412286?><pub-id pub-id-type="pmid">27412286</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0210041.ref018">
                <label>18</label>
                <mixed-citation publication-type="journal"><name><surname>Harrington</surname><given-names>LC</given-names></name>, <name><surname>Scott</surname><given-names>TW</given-names></name>, <name><surname>Lerdthusnee</surname><given-names>K</given-names></name>, <name><surname>Coleman</surname><given-names>RC</given-names></name>, <name><surname>Costero</surname><given-names>A</given-names></name>, <name><surname>Clark</surname><given-names>GG</given-names></name>, <etal>et al</etal><article-title>Dispersal of the dengue vector Aedes aegypti within and between rural communities</article-title>. <source>Am J Trop Med Hyg</source>. <year>2005</year>;<volume>72</volume>: <fpage>209</fpage>–<lpage>220</lpage>. doi:72/2/209 [pii] <?supplied-pmid 15741559?><pub-id pub-id-type="pmid">15741559</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0210041.ref019">
                <label>19</label>
                <mixed-citation publication-type="book"><name><surname>Halloran</surname><given-names>ME</given-names></name>, <name><surname>Longini</surname><given-names>IM</given-names></name>, <name><surname>Struchiner</surname><given-names>CJ</given-names></name>. <source>Design and Analysis of Vaccine Studies</source>. <publisher-name>Springer</publisher-name>; <year>2010</year><pub-id pub-id-type="doi">10.1007/978-0-387-68636-3</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0210041.ref020">
                <label>20</label>
                <mixed-citation publication-type="journal"><name><surname>White</surname><given-names>MT</given-names></name>, <name><surname>Griffin</surname><given-names>JT</given-names></name>, <name><surname>Drakeley</surname><given-names>CJ</given-names></name>, <name><surname>Ghani</surname><given-names>AC</given-names></name>. <article-title>Heterogeneity in malaria exposure and vaccine response: implications for the interpretation of vaccine efficacy trials</article-title>. <source>Malar J</source>. <year>2010</year>;<volume>9</volume>: <fpage>82</fpage><pub-id pub-id-type="doi">10.1186/1475-2875-9-82</pub-id><?supplied-pmid 20331863?><pub-id pub-id-type="pmid">20331863</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0210041.ref021">
                <label>21</label>
                <mixed-citation publication-type="journal"><name><surname>Halloran</surname><given-names>ME</given-names></name>, <name><surname>Longini</surname><given-names>IM</given-names></name>, <name><surname>Struchiner</surname><given-names>CJ</given-names></name>. <article-title>Estimability and interpretation of vaccine efficacy using frailty mixing models</article-title>. <source>Am J Epidemiol</source>. <year>1996</year>;<fpage>144</fpage><pub-id pub-id-type="doi">10.1093/oxfordjournals.aje.a008858</pub-id><pub-id pub-id-type="pmid">8546115</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0210041.ref022">
                <label>22</label>
                <mixed-citation publication-type="journal"><name><surname>O’Hagan</surname><given-names>JJ</given-names></name>, <name><surname>Lipsitch</surname><given-names>M</given-names></name>, <name><surname>Hernán</surname><given-names>MA</given-names></name>. <article-title>Estimating the per-exposure effect of infectious disease interventions</article-title>. <source>Epidemiology</source>. NIH Public Access; <year>2014</year>;<volume>25</volume>: <fpage>134</fpage><pub-id pub-id-type="doi">10.1097/EDE.0000000000000003</pub-id><?supplied-pmid 24240656?><pub-id pub-id-type="pmid">24240656</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0210041.ref023">
                <label>23</label>
                <mixed-citation publication-type="journal"><name><surname>Edelman</surname><given-names>R</given-names></name>, <name><surname>Hombach</surname><given-names>J</given-names></name>. <article-title>“Guidelines for the clinical evaluation of dengue vaccines in endemic areas”: Summary of a World Health Organization Technical Consultation</article-title>. <source>Vaccine</source>. <year>2008</year> pp. <fpage>4113</fpage>–<lpage>4119</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2008.05.058</pub-id>
<?supplied-pmid 18597906?><pub-id pub-id-type="pmid">18597906</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0210041.ref024">
                <label>24</label>
                <mixed-citation publication-type="journal"><name><surname>Morrison</surname><given-names>AC</given-names></name>, <name><surname>Minnick</surname><given-names>SL</given-names></name>, <name><surname>Rocha</surname><given-names>C</given-names></name>, <name><surname>Forshey</surname><given-names>BM</given-names></name>, <name><surname>Stoddard</surname><given-names>ST</given-names></name>, <name><surname>Getis</surname><given-names>A</given-names></name>, <etal>et al</etal><article-title>Epidemiology of dengue virus in Iquitos, Peru 1999 to 2005: interepidemic and epidemic patterns of transmission</article-title>. <source>PLoS Negl Trop Dis</source>. Public Library of Science; <year>2010</year>;<volume>4</volume>: <fpage>1</fpage>–<lpage>17</lpage>.</mixed-citation>
              </ref>
              <ref id="pone.0210041.ref025">
                <label>25</label>
                <mixed-citation publication-type="journal"><name><surname>Morrison</surname><given-names>a C</given-names></name>, <name><surname>Sihuincha</surname><given-names>M</given-names></name>, <name><surname>Stancil</surname><given-names>JD</given-names></name>, <name><surname>Zamora</surname><given-names>E</given-names></name>, <name><surname>Astete</surname><given-names>H</given-names></name>, <name><surname>Olson</surname><given-names>JG</given-names></name>, <etal>et al</etal><article-title>Aedes aegypti (Diptera: Culicidae) production from non-residential sites in the Amazonian city of Iquitos, Peru</article-title>. <source>Ann Trop Med Parasitol</source>. <year>2006</year>;<volume>100</volume><issue>Suppl</issue>: <fpage>S73</fpage>–<lpage>S86</lpage>. <pub-id pub-id-type="doi">10.1179/136485906X105534</pub-id>
<?supplied-pmid 16630393?><pub-id pub-id-type="pmid">16630393</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0210041.ref026">
                <label>26</label>
                <mixed-citation publication-type="journal"><name><surname>Getis</surname><given-names>A</given-names></name>, <name><surname>Morrison</surname><given-names>AC</given-names></name>, <name><surname>Gray</surname><given-names>K</given-names></name>, <name><surname>Scott</surname><given-names>TW</given-names></name>. <article-title>Characteristics of the spatial pattern of the dengue vector, Aedes aegypti, in Iquitos, Peru</article-title>. <source>Am J Trop Med Hyg</source>. <year>2003</year>;<volume>69</volume>: <fpage>494</fpage>–<lpage>505</lpage>. <pub-id pub-id-type="doi">10.1007/978-3-642-01976-0</pub-id>
<?supplied-pmid 14695086?><pub-id pub-id-type="pmid">14695086</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0210041.ref027">
                <label>27</label>
                <mixed-citation publication-type="journal"><name><surname>Reiner</surname><given-names>RC</given-names></name>, <name><surname>Stoddard</surname><given-names>ST</given-names></name>, <name><surname>Forshey</surname><given-names>BM</given-names></name>, <name><surname>King</surname><given-names>A a</given-names></name>, <name><surname>Ellis</surname><given-names>AM</given-names></name>, <name><surname>Lloyd</surname><given-names>AL</given-names></name>, <etal>et al</etal><article-title>Time-varying, serotype-specific force of infection of dengue virus</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2014</year>;<volume>111</volume>: <fpage>E2694</fpage>–<lpage>702</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1314933111</pub-id>
<?supplied-pmid 24847073?><pub-id pub-id-type="pmid">24847073</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0210041.ref028">
                <label>28</label>
                <mixed-citation publication-type="journal"><name><surname>Capeding</surname><given-names>MR</given-names></name>, <name><surname>Tran</surname><given-names>NH</given-names></name>, <name><surname>Hadinegoro</surname><given-names>SRS</given-names></name>, <name><surname>Ismail</surname><given-names>HIHJM</given-names></name>, <name><surname>Chotpitayasunondh</surname><given-names>T</given-names></name>, <name><surname>Chua</surname><given-names>MN</given-names></name>, <etal>et al</etal><article-title>Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial</article-title>. <source>Lancet</source>. <year>2014</year>;<volume>384</volume>: <fpage>1358</fpage>–<lpage>1365</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(14)61060-6</pub-id>
<?supplied-pmid 25018116?><pub-id pub-id-type="pmid">25018116</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0210041.ref029">
                <label>29</label>
                <mixed-citation publication-type="journal"><name><surname>Hadinegoro</surname><given-names>SR</given-names></name>, <name><surname>Arredondo-García</surname><given-names>JL</given-names></name>, <name><surname>Capeding</surname><given-names>MR</given-names></name>, <name><surname>Deseda</surname><given-names>C</given-names></name>, <name><surname>Chotpitayasunondh</surname><given-names>T</given-names></name>, <name><surname>Dietze</surname><given-names>R</given-names></name>, <etal>et al</etal><article-title>Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease</article-title>. <source>N Engl J Med</source>. <year>2015</year>; <fpage>1195</fpage>–<lpage>1206</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa1506223</pub-id>
<?supplied-pmid 26214039?><pub-id pub-id-type="pmid">26214039</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0210041.ref030">
                <label>30</label>
                <mixed-citation publication-type="journal"><name><surname>Villar</surname><given-names>L</given-names></name>, <name><surname>Dayan</surname><given-names>GH</given-names></name>, <name><surname>Arredondo-García</surname><given-names>JL</given-names></name>, <name><surname>Rivera</surname><given-names>DM</given-names></name>, <name><surname>Cunha</surname><given-names>R</given-names></name>, <name><surname>Deseda</surname><given-names>C</given-names></name>, <etal>et al</etal><article-title>Efficacy of a Tetravalent Dengue Vaccine in Children in Latin America</article-title>. <source>N Engl J Med</source>. <year>2015</year>;<volume>372</volume>: <fpage>113</fpage>–<lpage>123</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa1411037</pub-id>
<?supplied-pmid 25365753?><pub-id pub-id-type="pmid">25365753</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0210041.ref031">
                <label>31</label>
                <mixed-citation publication-type="other">ClinicalTrials.gov. Phase III Trial to Evaluate Efficacy and Safety of a Tetravalent Dengue Vaccine [Internet]. [cited 25 Mar 2018]. Available: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT02406729?cond=dengue+vaccine&amp;phase=2&amp;draw=2&amp;rank=11">https://clinicaltrials.gov/ct2/show/NCT02406729?cond=dengue+vaccine&amp;phase=2&amp;draw=2&amp;rank=11</ext-link></mixed-citation>
              </ref>
              <ref id="pone.0210041.ref032">
                <label>32</label>
                <mixed-citation publication-type="other">ClinicalTrials.gov. Efficacy, Safety and Immunogenicity of Takeda’s Tetravalent Dengue Vaccine (TDV) in Healthy Children [Internet]. [cited 25 Mar 2018]. Available: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/record/NCT02747927?term=takeda+dengue&amp;rank=3">https://clinicaltrials.gov/ct2/show/record/NCT02747927?term=takeda+dengue&amp;rank=3</ext-link></mixed-citation>
              </ref>
              <ref id="pone.0210041.ref033">
                <label>33</label>
                <mixed-citation publication-type="book"><name><surname>Morrow</surname><given-names>RH</given-names></name>, <name><surname>Smith</surname><given-names>PG</given-names></name>, <chapter-title>Special Programme for Research and Training in Tropical Diseases</chapter-title><source>Field trials of health interventions in developing countries: a toolbox</source>. <publisher-name>Macmillan</publisher-name>; <year>1996</year>.</mixed-citation>
              </ref>
              <ref id="pone.0210041.ref034">
                <label>34</label>
                <mixed-citation publication-type="journal"><name><surname>Sabchareon</surname><given-names>A</given-names></name>, <name><surname>Wallace</surname><given-names>D</given-names></name>, <name><surname>Sirivichayakul</surname><given-names>C</given-names></name>, <name><surname>Limkittikul</surname><given-names>K</given-names></name>, <name><surname>Chanthavanich</surname><given-names>P</given-names></name>, <name><surname>Suvannadabba</surname><given-names>S</given-names></name>, <etal>et al</etal><article-title>Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: A randomised, controlled phase 2b trial</article-title>. <source>Lancet</source>. <year>2012</year>;<volume>380</volume>: <fpage>1559</fpage>–<lpage>1567</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(12)61428-7</pub-id>
<?supplied-pmid 22975340?><pub-id pub-id-type="pmid">22975340</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0210041.ref035">
                <label>35</label>
                <mixed-citation publication-type="journal"><name><surname>Coudeville</surname><given-names>L</given-names></name>, <name><surname>Baurin</surname><given-names>N</given-names></name>, <name><surname>L’Azou</surname><given-names>M</given-names></name>, <name><surname>Guy</surname><given-names>B</given-names></name>. <article-title>Potential impact of dengue vaccination: Insights from two large-scale phase III trials with a tetravalent dengue vaccine</article-title>. <source>Vaccine</source>. <year>2016</year>;<volume>34</volume>: <fpage>6426</fpage>–<lpage>6435</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2016.08.050</pub-id>
<?supplied-pmid 27601343?><pub-id pub-id-type="pmid">27601343</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0210041.ref036">
                <label>36</label>
                <mixed-citation publication-type="journal"><name><surname>Hadinegoro</surname><given-names>S</given-names></name>, <name><surname>Arredondo-García</surname><given-names>J</given-names></name>, <name><surname>Capding</surname><given-names>M</given-names></name>. <article-title>Efficacy and safety of a novel tetravalent dengue vaccine in healthy children aged 2 to 14 years in Asia</article-title>. <source>Protocol</source>. <year>2010</year>.</mixed-citation>
              </ref>
              <ref id="pone.0210041.ref037">
                <label>37</label>
                <mixed-citation publication-type="journal"><name><surname>Stanaway</surname><given-names>JD</given-names></name>, <name><surname>Shepard</surname><given-names>DS</given-names></name>, <name><surname>Undurraga</surname><given-names>EA</given-names></name>, <name><surname>Halasa</surname><given-names>YA</given-names></name>, <name><surname>Coffeng</surname><given-names>LE</given-names></name>, <name><surname>Brady</surname><given-names>OJ</given-names></name>, <etal>et al</etal><article-title>The global burden of dengue: an analysis from the Global Burden of Disease Study 2013</article-title>. <source>Lancet Infect Dis. Elsevier</source>; <year>2016</year>;<volume>16</volume>: <fpage>712</fpage>–<lpage>723</lpage>. <pub-id pub-id-type="doi">10.1016/S1473-3099(16)00026-8</pub-id>
<?supplied-pmid 26874619?><pub-id pub-id-type="pmid">26874619</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0210041.ref038">
                <label>38</label>
                <mixed-citation publication-type="other">Dengue Branch C. Criteria for the Processing of Dengue Samples at the CDC Dengue Branch, San Juan, Puerto Rico [Internet]. 2011.</mixed-citation>
              </ref>
              <ref id="pone.0210041.ref039">
                <label>39</label>
                <mixed-citation publication-type="journal"><name><surname>Clapham</surname><given-names>HE</given-names></name>, <name><surname>Tricou</surname><given-names>V</given-names></name>, <name><surname>Van Vinh Chau</surname><given-names>N</given-names></name>, <name><surname>Simmons</surname><given-names>CP</given-names></name>, <name><surname>Ferguson</surname><given-names>NM</given-names></name>, <name><surname>Bhatt</surname><given-names>S</given-names></name>, <etal>et al</etal><article-title>Within-host viral dynamics of dengue serotype 1 infection</article-title>. <source>J R Soc Interface</source>. The Royal Society; <year>2014</year>;<volume>11</volume>: <fpage>504</fpage>–<lpage>507</lpage>. <pub-id pub-id-type="doi">10.1098/rsif.2014.0094</pub-id>
<?supplied-pmid 24829280?><pub-id pub-id-type="pmid">24829280</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0210041.ref040">
                <label>40</label>
                <mixed-citation publication-type="book"><collab>R Core Team</collab>. <source>R: A Language and Environment for Statistical Computing</source> [Internet]. <publisher-loc>Vienna, Austria, Austria</publisher-loc>; <year>2015</year> Available: <ext-link ext-link-type="uri" xlink:href="https://www.r-project.org/">https://www.r-project.org/</ext-link></mixed-citation>
              </ref>
              <ref id="pone.0210041.ref041">
                <label>41</label>
                <mixed-citation publication-type="other">Therneau TM. A Package for Survival Analysis in S [Internet]. 2015. Available: <ext-link ext-link-type="uri" xlink:href="http://cran.r-project.org/package=survival">http://cran.r-project.org/package=survival</ext-link></mixed-citation>
              </ref>
              <ref id="pone.0210041.ref042">
                <label>42</label>
                <mixed-citation publication-type="journal"><name><surname>Perkins</surname><given-names>A</given-names></name>, <name><surname>Reiner</surname><given-names>R</given-names></name>, <name><surname>España</surname><given-names>G</given-names></name>, <name><surname>ten Bosch</surname><given-names>QA</given-names></name>, <name><surname>Verma</surname><given-names>A</given-names></name>, <name><surname>Liebman</surname><given-names>K</given-names></name>, <etal>et al</etal><article-title>An agent-based model of dengue virus transmission shows how multiple uncertainties about vaccine efficacy influence public health impact projections</article-title>. <source>bioRxiv</source>. Cold Spring Harbor Laboratory; <year>2018</year>; <pub-id pub-id-type="doi">10.1101/082396</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0210041.ref043">
                <label>43</label>
                <mixed-citation publication-type="journal"><name><surname>Morrison</surname><given-names>AC</given-names></name>, <name><surname>Gray</surname><given-names>K</given-names></name>, <name><surname>Getis</surname><given-names>A</given-names></name>, <name><surname>Astete</surname><given-names>H</given-names></name>, <name><surname>Sihuincha</surname><given-names>M</given-names></name>, <name><surname>Focks</surname><given-names>D</given-names></name>, <etal>et al</etal><article-title>Temporal and Geographic Patterns of Aedes aegypti (Diptera: Culicidae) Production in Iquitos, Peru</article-title>. <source>J Med Entomol</source>. Entomological Society of America; <year>2004</year>;<volume>41</volume>: <fpage>1123</fpage>–<lpage>1142</lpage>. <pub-id pub-id-type="doi">10.1603/0022-2585-41.6.1123</pub-id>
<?supplied-pmid 15605653?><pub-id pub-id-type="pmid">15605653</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0210041.ref044">
                <label>44</label>
                <mixed-citation publication-type="journal"><name><surname>Paz-Soldan</surname><given-names>VA</given-names></name>, <name><surname>Stoddard</surname><given-names>ST</given-names></name>, <name><surname>Vazquez-Prokopec</surname><given-names>G</given-names></name>, <name><surname>Morrison</surname><given-names>AC</given-names></name>, <name><surname>Elder</surname><given-names>JP</given-names></name>, <name><surname>Kitron</surname><given-names>U</given-names></name>, <etal>et al</etal><article-title>Assessing and Maximizing the Acceptability of Global Positioning System Device Use for Studying the Role of Human Movement in Dengue Virus Transmission in Iquitos, Peru</article-title>. <source>Am J Trop Med Hyg</source>. <year>2010</year>;<volume>82</volume>: <fpage>723</fpage>–<lpage>730</lpage>. <pub-id pub-id-type="doi">10.4269/ajtmh.2010.09-0496</pub-id>
<?supplied-pmid 20348526?><pub-id pub-id-type="pmid">20348526</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0210041.ref045">
                <label>45</label>
                <mixed-citation publication-type="journal"><name><surname>Paz-Soldan</surname><given-names>VA</given-names></name>, <name><surname>Reiner</surname><given-names>RC</given-names></name>, <name><surname>Morrison</surname><given-names>AC</given-names></name>, <name><surname>Stoddard</surname><given-names>ST</given-names></name>, <name><surname>Kitron</surname><given-names>U</given-names></name>, <name><surname>Scott</surname><given-names>TW</given-names></name>, <etal>et al</etal><article-title>Strengths and Weaknesses of Global Positioning System (GPS) Data-Loggers and Semi-structured Interviews for Capturing Fine-scale Human Mobility: Findings from Iquitos, Peru</article-title>. <name><surname>Jones</surname><given-names>MK</given-names></name>, editor. <source>PLoS Negl Trop Dis</source>. Public Library of Science; <year>2014</year>;<volume>8</volume>: <fpage>1</fpage>–<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1371/journal.pntd.0002888</pub-id>
<?supplied-pmid 24922530?><pub-id pub-id-type="pmid">24922530</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0210041.ref046">
                <label>46</label>
                <mixed-citation publication-type="journal"><name><surname>Flasche</surname><given-names>S</given-names></name>, <name><surname>Jit</surname><given-names>M</given-names></name>, <name><surname>Rodríguez-Barraquer</surname><given-names>I</given-names></name>, <name><surname>Coudeville</surname><given-names>L</given-names></name>, <name><surname>Recker</surname><given-names>M</given-names></name>, <name><surname>Koelle</surname><given-names>K</given-names></name>, <etal>et al</etal><article-title>The Long-Term Safety, Public Health Impact, and Cost-Effectiveness of Routine Vaccination with a Recombinant, Live-Attenuated Dengue Vaccine (Dengvaxia): A Model Comparison Study</article-title>. <name><surname>von Seidlein</surname><given-names>L</given-names></name>, editor. <source>PLOS Med</source>. Public Library of Science; <year>2016</year>;<volume>13</volume>: <fpage>1</fpage>–<lpage>19</lpage>. <pub-id pub-id-type="doi">10.1371/journal.pmed.1002181</pub-id>
<?supplied-pmid 27898668?><pub-id pub-id-type="pmid">27898668</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0210041.ref047">
                <label>47</label>
                <mixed-citation publication-type="journal"><name><surname>España</surname><given-names>G</given-names></name>, <name><surname>Yao</surname><given-names>Y</given-names></name>, <name><surname>Anderson</surname><given-names>KB</given-names></name>, <name><surname>Fitzpatrick</surname><given-names>MC</given-names></name>, <name><surname>Smith</surname><given-names>DL</given-names></name>, <name><surname>Morrison</surname><given-names>AC</given-names></name>, <etal>et al</etal><article-title>Model-based assessment of public health impact and cost-effectiveness of dengue vaccination following screening for prior exposure</article-title>. <source>bioRxiv</source>. Cold Spring Harbor Laboratory; <year>2018</year>; <pub-id pub-id-type="doi">10.1101/367060</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0210041.ref048">
                <label>48</label>
                <mixed-citation publication-type="journal"><name><surname>Magori</surname><given-names>K</given-names></name>, <name><surname>Legros</surname><given-names>M</given-names></name>, <name><surname>Puente</surname><given-names>ME</given-names></name>, <name><surname>Focks</surname><given-names>DA</given-names></name>, <name><surname>Scott</surname><given-names>TW</given-names></name>, <name><surname>Lloyd</surname><given-names>AL</given-names></name>, <etal>et al</etal><article-title>Skeeter Buster: A Stochastic, Spatially Explicit Modeling Tool for Studying Aedes aegypti Population Replacement and Population Suppression Strategies</article-title>. <source>PLoS Negl Trop Dis</source>. <year>2009</year>;<volume>3</volume>: <fpage>1</fpage>–<lpage>18</lpage>. <pub-id pub-id-type="doi">10.1371/journal.pntd.0000508</pub-id>
<?supplied-pmid 19721700?><pub-id pub-id-type="pmid">19721700</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0210041.ref049">
                <label>49</label>
                <mixed-citation publication-type="journal"><name><surname>Yang</surname><given-names>HM</given-names></name>, <name><surname>Macoris</surname><given-names>MLG</given-names></name>, <name><surname>Galvani</surname><given-names>KC</given-names></name>, <name><surname>Andrighetti</surname><given-names>MTM</given-names></name>, <name><surname>Wanderley</surname><given-names>DM V</given-names></name>. <article-title>Assessing the effects of temperature on the population of Aedes aegypti, the vector of dengue</article-title>. <source>Epidemiol Infect</source>. Cambridge Univ Press; <year>2009</year>;<volume>137</volume>: <fpage>1188</fpage>–<lpage>1202</lpage>. <pub-id pub-id-type="doi">10.1017/S0950268809002040</pub-id>
<?supplied-pmid 19192322?><pub-id pub-id-type="pmid">19192322</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0210041.ref050">
                <label>50</label>
                <mixed-citation publication-type="journal"><name><surname>Reiner</surname><given-names>R</given-names></name>, <name><surname>Stoddard</surname><given-names>S</given-names></name>, <name><surname>Vazquez-Prokopec</surname><given-names>G</given-names></name>, <name><surname>Astete</surname><given-names>H</given-names></name>, <name><surname>Perkins</surname><given-names>TA</given-names></name>, <name><surname>Sihuincha</surname><given-names>M</given-names></name>, <etal>et al</etal><article-title>Estimating the impact of city-wide Aedes aegypti population control: An observational study in Iquitos, Peru</article-title>. <source>bioRxiv</source>. Cold Spring Harbor Laboratory; <year>2018</year>; <pub-id pub-id-type="doi">10.1101/265751</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0210041.ref051">
                <label>51</label>
                <mixed-citation publication-type="journal"><name><surname>Focks</surname><given-names>D a</given-names></name>, <name><surname>Haile</surname><given-names>DG</given-names></name>, <name><surname>Daniels</surname><given-names>E</given-names></name>, <name><surname>Mount</surname><given-names>G a</given-names></name>. <article-title>Dynamic life table model for Aedes aegypti (diptera: Culicidae): simulation results and validation</article-title>. <source>J Med Entomol</source>. <year>1993</year>;<volume>30</volume>: <fpage>1003</fpage>–<lpage>1017</lpage>. <pub-id pub-id-type="doi">10.1093/jmedent/30.6.1018</pub-id>
<?supplied-pmid 8271242?><pub-id pub-id-type="pmid">8271242</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0210041.ref052">
                <label>52</label>
                <mixed-citation publication-type="journal"><name><surname>Otero</surname><given-names>M</given-names></name>, <name><surname>Solari</surname><given-names>HG</given-names></name>, <name><surname>Schweigmann</surname><given-names>N</given-names></name>. <article-title>A Stochastic Population Dynamics Model for Aedes Aegypti: Formulation and Application to a City with Temperate Climate</article-title>. <source>Bull Math Biol</source>. <year>2006</year>;<volume>68</volume>: <fpage>1945</fpage>–<lpage>1974</lpage>. <pub-id pub-id-type="doi">10.1007/s11538-006-9067-y</pub-id>
<?supplied-pmid 16832731?><pub-id pub-id-type="pmid">16832731</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0210041.ref053">
                <label>53</label>
                <mixed-citation publication-type="journal"><name><surname>Scott</surname><given-names>TW</given-names></name>, <name><surname>Amerasinghe</surname><given-names>PH</given-names></name>, <name><surname>Morrison a</surname><given-names>C</given-names></name>, <name><surname>Lorenz</surname><given-names>LH</given-names></name>, <name><surname>Clark</surname><given-names>GG</given-names></name>, <name><surname>Strickman</surname><given-names>D</given-names></name>, <etal>et al</etal><article-title>Longitudinal studies of Aedes aegypti (Diptera: Culicidae) in Thailand and Puerto Rico: blood feeding frequency</article-title>. <source>J Med Entomol</source>. <year>2000</year>;<volume>37</volume>: <fpage>89</fpage>–<lpage>101</lpage>. <pub-id pub-id-type="doi">10.1603/0022-2585-37.1.77</pub-id>
<?supplied-pmid 15218911?><pub-id pub-id-type="pmid">15218911</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0210041.ref054">
                <label>54</label>
                <mixed-citation publication-type="journal"><name><surname>Ellis</surname><given-names>AM</given-names></name>, <name><surname>Garcia</surname><given-names>AJ</given-names></name>, <name><surname>Focks</surname><given-names>DA</given-names></name>, <name><surname>Morrison</surname><given-names>AC</given-names></name>, <name><surname>Scott</surname><given-names>TW</given-names></name>. <article-title>Parameterization and Sensitivity Analysis of a Complex Simulation Model for Mosquito Population Dynamics, Dengue Transmission, and Their Control</article-title>. <source>Am J Trop Med Hyg</source>. <year>2011</year>;<volume>85</volume>: <fpage>257</fpage>–<lpage>264</lpage>. <pub-id pub-id-type="doi">10.4269/ajtmh.2011.10-0516</pub-id>
<?supplied-pmid 21813844?><pub-id pub-id-type="pmid">21813844</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0210041.ref055">
                <label>55</label>
                <mixed-citation publication-type="journal"><name><surname>Chan</surname><given-names>M</given-names></name>, <name><surname>Johansson</surname><given-names>MA</given-names></name>. <article-title>The Incubation Periods of Dengue Viruses</article-title>. <source>PLoS One</source>. <year>2012</year>;<volume>7</volume>: <fpage>1</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0050972</pub-id>
<?supplied-pmid 23226436?><pub-id pub-id-type="pmid">23226436</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0210041.ref056">
                <label>56</label>
                <mixed-citation publication-type="journal"><name><surname>ten Bosch</surname><given-names>QA</given-names></name>, <name><surname>Clapham</surname><given-names>HE</given-names></name>, <name><surname>Lambrechts</surname><given-names>L</given-names></name>, <name><surname>Duong</surname><given-names>V</given-names></name>, <name><surname>Buchy</surname><given-names>P</given-names></name>, <name><surname>Althouse</surname><given-names>BM</given-names></name>, <etal>et al</etal><article-title>Contributions from the silent majority dominate dengue virus transmission</article-title>. <source>PLOS Pathog</source>. Public Library of Science; <year>2018</year>;<volume>14</volume>: <fpage>1</fpage>–<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1371/journal.ppat.1006965</pub-id>
<?supplied-pmid 29723307?><pub-id pub-id-type="pmid">29723307</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0210041.ref057">
                <label>57</label>
                <mixed-citation publication-type="journal"><name><surname>Reich</surname><given-names>NG</given-names></name>, <name><surname>Shrestha</surname><given-names>S</given-names></name>, <name><surname>King</surname><given-names>AA</given-names></name>, <name><surname>Rohani</surname><given-names>P</given-names></name>, <name><surname>Lessler</surname><given-names>J</given-names></name>, <name><surname>Kalayanarooj</surname><given-names>S</given-names></name>, <etal>et al</etal><article-title>Interactions between serotypes of dengue highlight epidemiological impact of cross-immunity</article-title>. <source>J R Soc Interface</source>. The Royal Society; <year>2013</year>;<volume>10</volume><pub-id pub-id-type="doi">10.1098/rsif.2013.0414</pub-id><?supplied-pmid 23825116?><pub-id pub-id-type="pmid">23825116</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0210041.ref058">
                <label>58</label>
                <mixed-citation publication-type="other">United Nations, Department of Economic and Social Affairs PD. World population prospects: The 2015 revision—SPecial Aggregates. DVD Editio. 2015.</mixed-citation>
              </ref>
              <ref id="pone.0210041.ref059">
                <label>59</label>
                <mixed-citation publication-type="book"><name><surname>Takken</surname><given-names>W</given-names></name>, <name><surname>Scott</surname><given-names>TW</given-names></name>. <source>Ecological aspects for application of genetically modified mosquitoes</source>. <publisher-name>Springer Science &amp; Business Media</publisher-name>; <year>2003</year>.</mixed-citation>
              </ref>
              <ref id="pone.0210041.ref060">
                <label>60</label>
                <mixed-citation publication-type="journal"><name><surname>Reiner</surname><given-names>RC</given-names><suffix>Jr.</suffix></name>, <name><surname>Achee</surname><given-names>N</given-names></name>, <name><surname>Barrera</surname><given-names>R</given-names></name>, <name><surname>Burkot</surname><given-names>TR</given-names></name>, <name><surname>Chadee</surname><given-names>DD</given-names></name>, <name><surname>Devine</surname><given-names>GJ</given-names></name>, <etal>et al</etal><article-title>Quantifying the Epidemiological Impact of Vector Control on Dengue</article-title>. <source>PLoS Negl Trop Dis</source>. Public Library of Science; <year>2016</year>;<volume>10</volume>: <fpage>1</fpage>–<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1371/journal.pntd.0004588</pub-id>
<?supplied-pmid 27227829?><pub-id pub-id-type="pmid">27227829</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0210041.ref061">
                <label>61</label>
                <mixed-citation publication-type="journal"><name><surname>Ferguson</surname><given-names>NM</given-names></name>, <name><surname>Rodríguez-Barraquer</surname><given-names>I</given-names></name>, <name><surname>Dorigatti</surname><given-names>I</given-names></name>, <name><surname>Mier-y-Teran-Romero</surname><given-names>L</given-names></name>, <name><surname>Laydon</surname><given-names>DJ</given-names></name>, <name><surname>Cummings</surname><given-names>DAT</given-names></name>. <article-title>Benefits and risks of the Sanofi-Pasteur dengue vaccine: Modeling optimal deployment</article-title>. <source>Science (80-)</source>. <year>2016</year>;<volume>353</volume>: <fpage>1033</fpage>–<lpage>1036</lpage>.</mixed-citation>
              </ref>
              <ref id="pone.0210041.ref062">
                <label>62</label>
                <mixed-citation publication-type="journal"><name><surname>Kahn</surname><given-names>R</given-names></name>, <name><surname>Hitchings</surname><given-names>M</given-names></name>, <name><surname>Wang</surname><given-names>R</given-names></name>, <name><surname>Bellan</surname><given-names>S</given-names></name>, <name><surname>Lipsitch</surname><given-names>M</given-names></name>. <article-title>Analyzing Vaccine Trials in Epidemics with Mild and Asymptomatic Infection</article-title>. <source>Am J Epidemiol</source>. <year>2018</year>; kwy239. <pub-id pub-id-type="doi">10.1093/aje/kwy239</pub-id><?supplied-pmid 30329134?><pub-id pub-id-type="pmid">30329134</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0210041.ref063">
                <label>63</label>
                <mixed-citation publication-type="journal"><name><surname>Clapham</surname><given-names>HE</given-names></name>, <name><surname>Cummings</surname><given-names>DAT</given-names></name>, <name><surname>Johansson</surname><given-names>MA</given-names></name>. <article-title>Immune status alters the probability of apparent illness due to dengue virus infection: Evidence from a pooled analysis across multiple cohort and cluster studies</article-title>. <source>PLoS Negl Trop Dis</source>. Public Library of Science; <year>2017</year>;<volume>11</volume>: <fpage>1</fpage>–<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1371/journal.pntd.0005926</pub-id>
<?supplied-pmid 28953902?><pub-id pub-id-type="pmid">28953902</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0210041.ref064">
                <label>64</label>
                <mixed-citation publication-type="journal"><name><surname>Rodriguez-Barraquer</surname><given-names>I</given-names></name>, <name><surname>Mier-y-Teran-Romero</surname><given-names>L</given-names></name>, <name><surname>Burke</surname><given-names>DS</given-names></name>, <name><surname>Cummings</surname><given-names>DAT</given-names></name>. <article-title>Challenges in the interpretation of dengue vaccine trial results</article-title>. <source>PLoS Negl Trop Dis</source>. Public Library of Science; <year>2013</year>;<volume>7</volume>: <fpage>1</fpage>–<lpage>3</lpage>. <pub-id pub-id-type="doi">10.1371/journal.pntd.0002126</pub-id>
<?supplied-pmid 24009782?><pub-id pub-id-type="pmid">24009782</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0210041.ref065">
                <label>65</label>
                <mixed-citation publication-type="journal"><name><surname>Longini</surname><given-names>IM</given-names></name>, <name><surname>Halloran</surname><given-names>ME</given-names></name>. <article-title>A frailty mixture model for estimating vaccine efficacy</article-title>. <source>J R Stat Soc Ser C</source> (Applied Stat. <year>1996</year>;<volume>45</volume>: <fpage>165</fpage>–<lpage>173</lpage>. <pub-id pub-id-type="doi">10.2307/2986152</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0210041.ref066">
                <label>66</label>
                <mixed-citation publication-type="journal"><name><surname>Halloran</surname><given-names>ME</given-names></name>, <name><surname>Auranen</surname><given-names>K</given-names></name>, <name><surname>Baird</surname><given-names>S</given-names></name>, <name><surname>Basta</surname><given-names>NE</given-names></name>, <name><surname>Bellan</surname><given-names>SE</given-names></name>, <name><surname>Brookmeyer</surname><given-names>R</given-names></name>, <etal>et al</etal><article-title>Simulations for designing and interpreting intervention trials in infectious diseases</article-title>. <source>BMC Med</source>. <year>2017</year>;<volume>15</volume>: <fpage>223</fpage><pub-id pub-id-type="doi">10.1186/s12916-017-0985-3</pub-id><?supplied-pmid 29287587?><pub-id pub-id-type="pmid">29287587</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
